Which perioperative strategies for transvaginal cervical cerclage are backed by data?

Article Type
Changed
Tue, 08/28/2018 - 11:02
Display Headline
Which perioperative strategies for transvaginal cervical cerclage are backed by data?

In contemporary medical practice, we expect our clinical actions to reflect the best and most current evidence. In many cases, however, the evidence available to us is weak or irrelevant. In their investigation, Berghella and colleagues set out to assess the quality of evidence in the setting of transvaginal cervical cerclage by reviewing the published data on selected perioperative strategies. They elected to perform a systematic review, as opposed to a narrative review (a simple opinion piece), because this approach follows an explicit process designed to limit bias and random error in the interpretation of scientific research.

The studies they analyzed vary from observational investigations to randomized trials, generating considerable heterogeneity in the data. Therefore, it would not have been feasible or appropriate for them to combine the results in a quantitative review (ie, meta-analysis). Their solution: to limit the analysis to a qualitative systematic review.

The term “systematic review” implies that investigators have an accurate and ­comprehensive understanding of existent data, with each study representing one contribution to a much larger body of knowledge. Over the years, Berghella and colleagues have contributed extensively to the literature on cervical cerclage and are well qualified to provide an analytic framework for the flood of published information on this practice. Although they focused primarily on how to perform cerclage, a discussion of when to ­perform cerclage cannot be separated from any consideration of efficacy.

When, exactly, is cerclage indicated?
The original indication for cerclage, established more than 50 years ago, required both a history of second-trimester loss and asymptomatic cervical changes in the current pregnancy. Since then, many cerclages have been performed on the basis of history alone or on current cervical changes regardless of history. However, the most recent professional guidelines reconfirm that any cerclage procedure should be supported by both historical and contemporaneous findings.1,2 

Investigators have demonstrated that the measurement of cervical length by ­transvaginal ultrasound should generally be an integral part of clinical evaluation for asymptomatic cervical changes. Indeed, sonographic assessment has emerged as a tool capable of reducing “overcall” and unnecessary intervention.3 On the other hand, a meta-analysis of four randomized trials of ultrasound-indicated cerclage found it to be beneficial in women with a short cervix only if they also had a history of preterm delivery.4

In addition, randomized trials have documented a benefit for cerclage in two other clinical contexts:

  • Results from a secondary analysis of data from a large randomized trial published in 1993 suggest that elective cerclage can be based on history alone in women with three or more second-trimester losses or preterm births.5
  • Authors of a randomized trial published in 2003 ­suggested that women with advanced cervical changes, such as dilatation of the external os with exposure of the fetal membranes, may benefit from “emergency” cerclage even in the absence of a prior preterm delivery.6

How the data were analyzed
The data included in the review were analyzed separately, according to three widely accepted indications for cerclage:

  • history-indicated: a history of three or more second-trimester losses and/or preterm births
  • ultrasound-indicated: ultrasonographic detection of a cervical length of less than 25 mm, as measured by transvaginal ultrasound, in a woman with a history of second-trimester loss or preterm birth
  • physical-examination–indicated: physical examination (manual or with a speculum) that confirms a dilated cervix.

Granted, this terminology can be confusing, as in the case of ultrasound-indicated cerclage, which includes aspects of the patient’s history. Moreover, I doubt that the studies included in this analysis always adhered to these definitions. The heterogeneity of the study population and the ambiguity of these definitions may limit the applicability of findings. In fact, they constitute the major (albeit practically unavoidable) limitation of this review.

The optimal approach to subclinical infection is unclear
Although there is a consensus that overt intra-amniotic infection is an absolute contraindication to cerclage, the implications of subclinical intra-amniotic infection in asymptomatic women are unclear. About 50% of women considered for emergency cerclage are likely to have intra-amniotic infection.7 An ongoing randomized trial is expected to elucidate the benefit of precerclage amniocentesis in such cases.

The sonographic detection of sludge in the amniotic fluid also has been associated with intra-amniotic infection. However, after analyzing the data, Berghella and colleagues did not find adequate justification for amniocentesis in this setting. A more practical question might be whether cerclage is advisable at all when sludge is present. Data from a recently reported abstract suggest that the presence of sludge increases the likelihood of early preterm birth independent of cervical length.8

Other gray areas
Another absolute contraindication to cerclage is the presence of painful uterine contractions in a woman exhibiting cervical change. The study findings seemed to imply that when uterine contractions are detected via tocodynamometric monitoring but are not experienced by the patient, cerclage may be appropriate. In my opinion, this issue represents another open clinical question.

 

 

On at least one occasion, I have discovered that the patient scheduled for cerclage has not undergone preoperative screening for genital tract infections. In such a scenario, it is unclear whether it is best to cancel the procedure or to proceed. Berghella and colleagues concluded that evidence is insufficient to support routine, universal screening for genital tract infection prior to cerclage. In the absence of risk factors for infection, it may be appropriate to proceed with cerclage.

The issue of combined use of cerclage and 17α hydroxyprogesterone caproate also was addressed in this review. Berghella and colleagues recommended that progestin supplementation be continued if cerclage is subsequently performed. I, too, follow this approach, although the two interventions (progestin followed by cerclage) have not been studied in this sequence.

Related article: A stepwise approach to cervical cerclage (June 2012)

Data are limited, and conflicting, on the use of 17α hydroxyprogesterone caproate after cerclage. A small randomized trial suggested benefit,9 while a retrospective cohort study10 and a secondary analysis of data from a randomized trial of cerclage11 found no benefit for the addition of 17α hydroxyprogesterone caproate.

Berghella and colleagues advocated against reinforcing (second or repeat) cerclage, an intervention that may be associated with a higher incidence of preterm birth.12 Accordingly, continuing sonographic assessment of cervical length after cerclage may be futile.   What this evidence means for practice
Increasing evidence suggests that cervical shortening is not limited to an innate or acquired cervical weakness but represents an early, asymptomatic phase on the pathway to preterm birth. Nevertheless, cerclage continues to be practiced widely and has been shown to be beneficial in selected populations.

We clinicians often face complex cases of presumed cervical insufficiency for which there are no simple or unequivocal recommendations. This appraisal by Berghella and colleagues will help us separate evidence-validated approaches from misconceptions in the technical aspects of cerclage.
--Alex C. Vidaeff, MD, MPH

We want to hear from you! Tell us what you think.

References

  1. Royal College of Obstetricians and Gynaecologists. Cervical cerclage [guidelines]. http://www.rcog.org.uk/womens-health/clinical-guidance/cervical-cerclage-green-top-60. Accessed September 18, 2013.
  2. ACOG Practice Bulletin #130: Prediction and prevention of preterm birth. Obstet Gynecol. 2012;120:964–973.
  3. Grimes-Dennis J, Berghella V. Cervical length and prediction of preterm delivery. Curr Opin Obstet Gynecol. 2007;19(2):191–195.
  4. Berghella V, Odibo AO, To MS, et al. Cerclage for short cervix on ultrasound: meta-analysis of trials using individual patient-level data. Obstet Gynecol. 2005;106(1):181–189.
  5. Working Party on Cervical Cerclage. Final report of the Medical Research Council/Royal College of Obstetricians and Gynaecologists multicenter randomised trial of cervical cerclage. Br J Obstet Gynaecol. 1993;100(6):516–523.
  6. Althuisius SM, Dekker GA, Hummel P, van Geijin HP. Cervical incompetence prevention randomized cerclage trial: emergency cerclage with bed rest versus bed rest alone. Am J Obstet Gynecol. 2003;189(4):907–910.
  7. Romero R, Gonzalez R, Sepulveda W, et al. Infection and labor. VIII. Microbial invasion of the amniotic cavity in patients with suspected cervical incompetence: prevalence and clinical significance. Am J Obstet Gynecol. 1992(4 Pt 1);167:1086–1091.
  8. Saade G. Cervical funneling or intraamniotic debris and preterm birth in nulliparous women with short cervix. Am J Obstet Gynecol. 2013;208(1):S4.
  9. Yemini M, Borenstein R, Dreazen E, et al. Prevention of premature labor by 17 alpha-hydroxyprogesterone caproate. Am J Obstet Gynecol. 1985;151(5):574–577.
  10. Rebarber A, Cleary-Goldman J, Istwan NB, et al. The use of 17 alpha-hydroxyprogesterone caproate (17P) in women with cervical cerclage. Am J Perinatol. 2008;25(5):271–275.
  11. Berghella V, Figueroa D, Szychowski JM, et al. 17 alpha-hydroxyprogesterone caproate for the prevention of preterm birth in women with prior preterm birth and a short cervical length. Am J Obstet Gynecol. 2010;202(4):351.e1–e6.
  12. Baxter JK, Airoldi J, Berghella V. Short cervical length after history-indicated cerclage: is a reinforcing cerclage beneficial? Am J Obstet Gynecol. 2005;193(3 Pt 2):1204–1207. 
Author and Disclosure Information

EXPERT COMMENTARY
Alex C. Vidaeff, MD, MPH,
Professor, Division of Maternal-Fetal Medicine, Department of Obstetrics and Gynecology, Baylor College of Medicine, Houston, Texas.

Issue
OBG Management - 25(10)
Publications
Topics
Page Number
14-17, 24
Legacy Keywords
Which perioperative strategies for transvaginal cervical cerclage are backed by data?, Alex C. Vidaeff MD MPH, cervical cerclage, perioperative strategies, transvaginal cervical cerclage, McDonald cerclage, single stitch, high placement, outpatient setting, evidence, supported by evidence
Sections
Author and Disclosure Information

EXPERT COMMENTARY
Alex C. Vidaeff, MD, MPH,
Professor, Division of Maternal-Fetal Medicine, Department of Obstetrics and Gynecology, Baylor College of Medicine, Houston, Texas.

Author and Disclosure Information

EXPERT COMMENTARY
Alex C. Vidaeff, MD, MPH,
Professor, Division of Maternal-Fetal Medicine, Department of Obstetrics and Gynecology, Baylor College of Medicine, Houston, Texas.

In contemporary medical practice, we expect our clinical actions to reflect the best and most current evidence. In many cases, however, the evidence available to us is weak or irrelevant. In their investigation, Berghella and colleagues set out to assess the quality of evidence in the setting of transvaginal cervical cerclage by reviewing the published data on selected perioperative strategies. They elected to perform a systematic review, as opposed to a narrative review (a simple opinion piece), because this approach follows an explicit process designed to limit bias and random error in the interpretation of scientific research.

The studies they analyzed vary from observational investigations to randomized trials, generating considerable heterogeneity in the data. Therefore, it would not have been feasible or appropriate for them to combine the results in a quantitative review (ie, meta-analysis). Their solution: to limit the analysis to a qualitative systematic review.

The term “systematic review” implies that investigators have an accurate and ­comprehensive understanding of existent data, with each study representing one contribution to a much larger body of knowledge. Over the years, Berghella and colleagues have contributed extensively to the literature on cervical cerclage and are well qualified to provide an analytic framework for the flood of published information on this practice. Although they focused primarily on how to perform cerclage, a discussion of when to ­perform cerclage cannot be separated from any consideration of efficacy.

When, exactly, is cerclage indicated?
The original indication for cerclage, established more than 50 years ago, required both a history of second-trimester loss and asymptomatic cervical changes in the current pregnancy. Since then, many cerclages have been performed on the basis of history alone or on current cervical changes regardless of history. However, the most recent professional guidelines reconfirm that any cerclage procedure should be supported by both historical and contemporaneous findings.1,2 

Investigators have demonstrated that the measurement of cervical length by ­transvaginal ultrasound should generally be an integral part of clinical evaluation for asymptomatic cervical changes. Indeed, sonographic assessment has emerged as a tool capable of reducing “overcall” and unnecessary intervention.3 On the other hand, a meta-analysis of four randomized trials of ultrasound-indicated cerclage found it to be beneficial in women with a short cervix only if they also had a history of preterm delivery.4

In addition, randomized trials have documented a benefit for cerclage in two other clinical contexts:

  • Results from a secondary analysis of data from a large randomized trial published in 1993 suggest that elective cerclage can be based on history alone in women with three or more second-trimester losses or preterm births.5
  • Authors of a randomized trial published in 2003 ­suggested that women with advanced cervical changes, such as dilatation of the external os with exposure of the fetal membranes, may benefit from “emergency” cerclage even in the absence of a prior preterm delivery.6

How the data were analyzed
The data included in the review were analyzed separately, according to three widely accepted indications for cerclage:

  • history-indicated: a history of three or more second-trimester losses and/or preterm births
  • ultrasound-indicated: ultrasonographic detection of a cervical length of less than 25 mm, as measured by transvaginal ultrasound, in a woman with a history of second-trimester loss or preterm birth
  • physical-examination–indicated: physical examination (manual or with a speculum) that confirms a dilated cervix.

Granted, this terminology can be confusing, as in the case of ultrasound-indicated cerclage, which includes aspects of the patient’s history. Moreover, I doubt that the studies included in this analysis always adhered to these definitions. The heterogeneity of the study population and the ambiguity of these definitions may limit the applicability of findings. In fact, they constitute the major (albeit practically unavoidable) limitation of this review.

The optimal approach to subclinical infection is unclear
Although there is a consensus that overt intra-amniotic infection is an absolute contraindication to cerclage, the implications of subclinical intra-amniotic infection in asymptomatic women are unclear. About 50% of women considered for emergency cerclage are likely to have intra-amniotic infection.7 An ongoing randomized trial is expected to elucidate the benefit of precerclage amniocentesis in such cases.

The sonographic detection of sludge in the amniotic fluid also has been associated with intra-amniotic infection. However, after analyzing the data, Berghella and colleagues did not find adequate justification for amniocentesis in this setting. A more practical question might be whether cerclage is advisable at all when sludge is present. Data from a recently reported abstract suggest that the presence of sludge increases the likelihood of early preterm birth independent of cervical length.8

Other gray areas
Another absolute contraindication to cerclage is the presence of painful uterine contractions in a woman exhibiting cervical change. The study findings seemed to imply that when uterine contractions are detected via tocodynamometric monitoring but are not experienced by the patient, cerclage may be appropriate. In my opinion, this issue represents another open clinical question.

 

 

On at least one occasion, I have discovered that the patient scheduled for cerclage has not undergone preoperative screening for genital tract infections. In such a scenario, it is unclear whether it is best to cancel the procedure or to proceed. Berghella and colleagues concluded that evidence is insufficient to support routine, universal screening for genital tract infection prior to cerclage. In the absence of risk factors for infection, it may be appropriate to proceed with cerclage.

The issue of combined use of cerclage and 17α hydroxyprogesterone caproate also was addressed in this review. Berghella and colleagues recommended that progestin supplementation be continued if cerclage is subsequently performed. I, too, follow this approach, although the two interventions (progestin followed by cerclage) have not been studied in this sequence.

Related article: A stepwise approach to cervical cerclage (June 2012)

Data are limited, and conflicting, on the use of 17α hydroxyprogesterone caproate after cerclage. A small randomized trial suggested benefit,9 while a retrospective cohort study10 and a secondary analysis of data from a randomized trial of cerclage11 found no benefit for the addition of 17α hydroxyprogesterone caproate.

Berghella and colleagues advocated against reinforcing (second or repeat) cerclage, an intervention that may be associated with a higher incidence of preterm birth.12 Accordingly, continuing sonographic assessment of cervical length after cerclage may be futile.   What this evidence means for practice
Increasing evidence suggests that cervical shortening is not limited to an innate or acquired cervical weakness but represents an early, asymptomatic phase on the pathway to preterm birth. Nevertheless, cerclage continues to be practiced widely and has been shown to be beneficial in selected populations.

We clinicians often face complex cases of presumed cervical insufficiency for which there are no simple or unequivocal recommendations. This appraisal by Berghella and colleagues will help us separate evidence-validated approaches from misconceptions in the technical aspects of cerclage.
--Alex C. Vidaeff, MD, MPH

We want to hear from you! Tell us what you think.

In contemporary medical practice, we expect our clinical actions to reflect the best and most current evidence. In many cases, however, the evidence available to us is weak or irrelevant. In their investigation, Berghella and colleagues set out to assess the quality of evidence in the setting of transvaginal cervical cerclage by reviewing the published data on selected perioperative strategies. They elected to perform a systematic review, as opposed to a narrative review (a simple opinion piece), because this approach follows an explicit process designed to limit bias and random error in the interpretation of scientific research.

The studies they analyzed vary from observational investigations to randomized trials, generating considerable heterogeneity in the data. Therefore, it would not have been feasible or appropriate for them to combine the results in a quantitative review (ie, meta-analysis). Their solution: to limit the analysis to a qualitative systematic review.

The term “systematic review” implies that investigators have an accurate and ­comprehensive understanding of existent data, with each study representing one contribution to a much larger body of knowledge. Over the years, Berghella and colleagues have contributed extensively to the literature on cervical cerclage and are well qualified to provide an analytic framework for the flood of published information on this practice. Although they focused primarily on how to perform cerclage, a discussion of when to ­perform cerclage cannot be separated from any consideration of efficacy.

When, exactly, is cerclage indicated?
The original indication for cerclage, established more than 50 years ago, required both a history of second-trimester loss and asymptomatic cervical changes in the current pregnancy. Since then, many cerclages have been performed on the basis of history alone or on current cervical changes regardless of history. However, the most recent professional guidelines reconfirm that any cerclage procedure should be supported by both historical and contemporaneous findings.1,2 

Investigators have demonstrated that the measurement of cervical length by ­transvaginal ultrasound should generally be an integral part of clinical evaluation for asymptomatic cervical changes. Indeed, sonographic assessment has emerged as a tool capable of reducing “overcall” and unnecessary intervention.3 On the other hand, a meta-analysis of four randomized trials of ultrasound-indicated cerclage found it to be beneficial in women with a short cervix only if they also had a history of preterm delivery.4

In addition, randomized trials have documented a benefit for cerclage in two other clinical contexts:

  • Results from a secondary analysis of data from a large randomized trial published in 1993 suggest that elective cerclage can be based on history alone in women with three or more second-trimester losses or preterm births.5
  • Authors of a randomized trial published in 2003 ­suggested that women with advanced cervical changes, such as dilatation of the external os with exposure of the fetal membranes, may benefit from “emergency” cerclage even in the absence of a prior preterm delivery.6

How the data were analyzed
The data included in the review were analyzed separately, according to three widely accepted indications for cerclage:

  • history-indicated: a history of three or more second-trimester losses and/or preterm births
  • ultrasound-indicated: ultrasonographic detection of a cervical length of less than 25 mm, as measured by transvaginal ultrasound, in a woman with a history of second-trimester loss or preterm birth
  • physical-examination–indicated: physical examination (manual or with a speculum) that confirms a dilated cervix.

Granted, this terminology can be confusing, as in the case of ultrasound-indicated cerclage, which includes aspects of the patient’s history. Moreover, I doubt that the studies included in this analysis always adhered to these definitions. The heterogeneity of the study population and the ambiguity of these definitions may limit the applicability of findings. In fact, they constitute the major (albeit practically unavoidable) limitation of this review.

The optimal approach to subclinical infection is unclear
Although there is a consensus that overt intra-amniotic infection is an absolute contraindication to cerclage, the implications of subclinical intra-amniotic infection in asymptomatic women are unclear. About 50% of women considered for emergency cerclage are likely to have intra-amniotic infection.7 An ongoing randomized trial is expected to elucidate the benefit of precerclage amniocentesis in such cases.

The sonographic detection of sludge in the amniotic fluid also has been associated with intra-amniotic infection. However, after analyzing the data, Berghella and colleagues did not find adequate justification for amniocentesis in this setting. A more practical question might be whether cerclage is advisable at all when sludge is present. Data from a recently reported abstract suggest that the presence of sludge increases the likelihood of early preterm birth independent of cervical length.8

Other gray areas
Another absolute contraindication to cerclage is the presence of painful uterine contractions in a woman exhibiting cervical change. The study findings seemed to imply that when uterine contractions are detected via tocodynamometric monitoring but are not experienced by the patient, cerclage may be appropriate. In my opinion, this issue represents another open clinical question.

 

 

On at least one occasion, I have discovered that the patient scheduled for cerclage has not undergone preoperative screening for genital tract infections. In such a scenario, it is unclear whether it is best to cancel the procedure or to proceed. Berghella and colleagues concluded that evidence is insufficient to support routine, universal screening for genital tract infection prior to cerclage. In the absence of risk factors for infection, it may be appropriate to proceed with cerclage.

The issue of combined use of cerclage and 17α hydroxyprogesterone caproate also was addressed in this review. Berghella and colleagues recommended that progestin supplementation be continued if cerclage is subsequently performed. I, too, follow this approach, although the two interventions (progestin followed by cerclage) have not been studied in this sequence.

Related article: A stepwise approach to cervical cerclage (June 2012)

Data are limited, and conflicting, on the use of 17α hydroxyprogesterone caproate after cerclage. A small randomized trial suggested benefit,9 while a retrospective cohort study10 and a secondary analysis of data from a randomized trial of cerclage11 found no benefit for the addition of 17α hydroxyprogesterone caproate.

Berghella and colleagues advocated against reinforcing (second or repeat) cerclage, an intervention that may be associated with a higher incidence of preterm birth.12 Accordingly, continuing sonographic assessment of cervical length after cerclage may be futile.   What this evidence means for practice
Increasing evidence suggests that cervical shortening is not limited to an innate or acquired cervical weakness but represents an early, asymptomatic phase on the pathway to preterm birth. Nevertheless, cerclage continues to be practiced widely and has been shown to be beneficial in selected populations.

We clinicians often face complex cases of presumed cervical insufficiency for which there are no simple or unequivocal recommendations. This appraisal by Berghella and colleagues will help us separate evidence-validated approaches from misconceptions in the technical aspects of cerclage.
--Alex C. Vidaeff, MD, MPH

We want to hear from you! Tell us what you think.

References

  1. Royal College of Obstetricians and Gynaecologists. Cervical cerclage [guidelines]. http://www.rcog.org.uk/womens-health/clinical-guidance/cervical-cerclage-green-top-60. Accessed September 18, 2013.
  2. ACOG Practice Bulletin #130: Prediction and prevention of preterm birth. Obstet Gynecol. 2012;120:964–973.
  3. Grimes-Dennis J, Berghella V. Cervical length and prediction of preterm delivery. Curr Opin Obstet Gynecol. 2007;19(2):191–195.
  4. Berghella V, Odibo AO, To MS, et al. Cerclage for short cervix on ultrasound: meta-analysis of trials using individual patient-level data. Obstet Gynecol. 2005;106(1):181–189.
  5. Working Party on Cervical Cerclage. Final report of the Medical Research Council/Royal College of Obstetricians and Gynaecologists multicenter randomised trial of cervical cerclage. Br J Obstet Gynaecol. 1993;100(6):516–523.
  6. Althuisius SM, Dekker GA, Hummel P, van Geijin HP. Cervical incompetence prevention randomized cerclage trial: emergency cerclage with bed rest versus bed rest alone. Am J Obstet Gynecol. 2003;189(4):907–910.
  7. Romero R, Gonzalez R, Sepulveda W, et al. Infection and labor. VIII. Microbial invasion of the amniotic cavity in patients with suspected cervical incompetence: prevalence and clinical significance. Am J Obstet Gynecol. 1992(4 Pt 1);167:1086–1091.
  8. Saade G. Cervical funneling or intraamniotic debris and preterm birth in nulliparous women with short cervix. Am J Obstet Gynecol. 2013;208(1):S4.
  9. Yemini M, Borenstein R, Dreazen E, et al. Prevention of premature labor by 17 alpha-hydroxyprogesterone caproate. Am J Obstet Gynecol. 1985;151(5):574–577.
  10. Rebarber A, Cleary-Goldman J, Istwan NB, et al. The use of 17 alpha-hydroxyprogesterone caproate (17P) in women with cervical cerclage. Am J Perinatol. 2008;25(5):271–275.
  11. Berghella V, Figueroa D, Szychowski JM, et al. 17 alpha-hydroxyprogesterone caproate for the prevention of preterm birth in women with prior preterm birth and a short cervical length. Am J Obstet Gynecol. 2010;202(4):351.e1–e6.
  12. Baxter JK, Airoldi J, Berghella V. Short cervical length after history-indicated cerclage: is a reinforcing cerclage beneficial? Am J Obstet Gynecol. 2005;193(3 Pt 2):1204–1207. 
References

  1. Royal College of Obstetricians and Gynaecologists. Cervical cerclage [guidelines]. http://www.rcog.org.uk/womens-health/clinical-guidance/cervical-cerclage-green-top-60. Accessed September 18, 2013.
  2. ACOG Practice Bulletin #130: Prediction and prevention of preterm birth. Obstet Gynecol. 2012;120:964–973.
  3. Grimes-Dennis J, Berghella V. Cervical length and prediction of preterm delivery. Curr Opin Obstet Gynecol. 2007;19(2):191–195.
  4. Berghella V, Odibo AO, To MS, et al. Cerclage for short cervix on ultrasound: meta-analysis of trials using individual patient-level data. Obstet Gynecol. 2005;106(1):181–189.
  5. Working Party on Cervical Cerclage. Final report of the Medical Research Council/Royal College of Obstetricians and Gynaecologists multicenter randomised trial of cervical cerclage. Br J Obstet Gynaecol. 1993;100(6):516–523.
  6. Althuisius SM, Dekker GA, Hummel P, van Geijin HP. Cervical incompetence prevention randomized cerclage trial: emergency cerclage with bed rest versus bed rest alone. Am J Obstet Gynecol. 2003;189(4):907–910.
  7. Romero R, Gonzalez R, Sepulveda W, et al. Infection and labor. VIII. Microbial invasion of the amniotic cavity in patients with suspected cervical incompetence: prevalence and clinical significance. Am J Obstet Gynecol. 1992(4 Pt 1);167:1086–1091.
  8. Saade G. Cervical funneling or intraamniotic debris and preterm birth in nulliparous women with short cervix. Am J Obstet Gynecol. 2013;208(1):S4.
  9. Yemini M, Borenstein R, Dreazen E, et al. Prevention of premature labor by 17 alpha-hydroxyprogesterone caproate. Am J Obstet Gynecol. 1985;151(5):574–577.
  10. Rebarber A, Cleary-Goldman J, Istwan NB, et al. The use of 17 alpha-hydroxyprogesterone caproate (17P) in women with cervical cerclage. Am J Perinatol. 2008;25(5):271–275.
  11. Berghella V, Figueroa D, Szychowski JM, et al. 17 alpha-hydroxyprogesterone caproate for the prevention of preterm birth in women with prior preterm birth and a short cervical length. Am J Obstet Gynecol. 2010;202(4):351.e1–e6.
  12. Baxter JK, Airoldi J, Berghella V. Short cervical length after history-indicated cerclage: is a reinforcing cerclage beneficial? Am J Obstet Gynecol. 2005;193(3 Pt 2):1204–1207. 
Issue
OBG Management - 25(10)
Issue
OBG Management - 25(10)
Page Number
14-17, 24
Page Number
14-17, 24
Publications
Publications
Topics
Article Type
Display Headline
Which perioperative strategies for transvaginal cervical cerclage are backed by data?
Display Headline
Which perioperative strategies for transvaginal cervical cerclage are backed by data?
Legacy Keywords
Which perioperative strategies for transvaginal cervical cerclage are backed by data?, Alex C. Vidaeff MD MPH, cervical cerclage, perioperative strategies, transvaginal cervical cerclage, McDonald cerclage, single stitch, high placement, outpatient setting, evidence, supported by evidence
Legacy Keywords
Which perioperative strategies for transvaginal cervical cerclage are backed by data?, Alex C. Vidaeff MD MPH, cervical cerclage, perioperative strategies, transvaginal cervical cerclage, McDonald cerclage, single stitch, high placement, outpatient setting, evidence, supported by evidence
Sections
Article Source

PURLs Copyright

Inside the Article

In young hysterectomized women, does unopposed estrogen therapy increase overall survival?

Article Type
Changed
Tue, 08/28/2018 - 11:02
Display Headline
In young hysterectomized women, does unopposed estrogen therapy increase overall survival?

During the 1990s, more than 90% of hysterectomized women aged 50 to 59 years used ET following the procedure. When the initial findings of the WHI were published in 2002, they prompted many women to refuse or discontinue ET—despite the fact that the initial findings concerned the use of estrogen and progestin in combination in women with an intact uterus. Today, only some 30% of women use ET after hysterectomy.

When findings from the WHI estrogen-only arm were eventually published, they revealed that ET reduces mortality among women 50 to 59 years old, compared with placebo. Although most of the reduction in mortality relates to fewer deaths from coronary heart disease, a decline in deaths from breast cancer also was seen.2,3

Sarrel and colleagues calculated the excess mortality among US women aged 50 to 59 that could have been prevented by ET during the decade from 2002 through 2011. Their estimates ranged from approximately 19,000 deaths to as many as 92,000 deaths.

By calling attention to the negative health consequences of estrogen avoidance in young hysterectomized women, Sarrel and colleagues have performed a valuable public service.

Plethora of WHI data may have contributed to confusion

The WHI clinical trials have produced numerous analyses in various subsets of women. The sheer volume of data may be daunting in some cases, and likely has led to a failure to distinguish between estrogen-only and estrogen-progestin therapy, which have very different safety profiles.

Further, some clinicians and many patients have overlooked the fact that the risk-benefit profile of hormone therapy (both estrogen-only and estrogen-progestin therapy) is more favorable in younger, recently menopausal women than it is in older women.

I encounter evidence of this unwarranted fear of ET in my practice, with highly symptomatic, recently menopausal women who are appropriate candidates for hormone therapy electing to refuse the most effective treatment for menopausal symptoms.

Of course, hormone therapy, like all medications, has risks as well as benefits. For example, oral ET increases the risk of venous thrombosis and stroke, and long-term use of estrogen-progestin therapy increases the risk of breast cancer. However, the overblown fears of estrogen therapy have caused many appropriate candidates to miss out on symptom relief, prevention of osteoporosis, and treatment of symptomatic genital atrophy.

What this evidence means for practice
This provocative report demonstrates that wholesale avoidance of hormone therapy can have important negative public health consequence.
--Andrew M. Kaunitz, MD

We want to hear from you! Tell us what you think.

References

1. Rossouw JE, Anderson GL, Prentice RL, et al; Writing Group for the Women’s Health Initiative Investigators. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results From the Women’s Health Initiative randomized controlled trial. JAMA. 2002;288(3):321–333.

2. LaCroix AZ, Chlebowski RT, Manson JE, et al; WHI Investigators. Health outcomes after stopping conjugated equine estrogens among postmenopausal women with prior hysterectomy: a randomized controlled trial. JAMA. 2011;305(13):1305–1314.

3. Anderson GL, Chlebowski RI, Aragaki AK, et al. Conjugated equine estrogen and breast cancer incidence and mortality in postmenopausal women with hysterectomy: extended follow-up of the Women’s Health Initiative randomized placebo-controlled trial. Lancet Oncol. 2012; 13(5):476–486.

Article PDF
Author and Disclosure Information

EXPERT COMMENTARY
Andrew M. Kaunitz, MD
, Professor and Associate Chairman, Department of Obstetrics & Gynecology, University of Florida College of Medicine–Jacksonville, Jacksonville, Florida. Dr. Kaunitz serves on the OBG Management Board of Editors.

Issue
OBG Management - 25(10)
Publications
Topics
Page Number
55-56
Legacy Keywords
survival, In young hysterectomized women, does unopposed estrogen therapy increase overall survival?, unopposed estrogen therapy, estrogen therapy, ET, unopposed ET, hysterectomy, younger age, young women, hysterectomy, WHI, women's health initiative, preventable death, Andrew M. Kaunitz MD
Sections
Author and Disclosure Information

EXPERT COMMENTARY
Andrew M. Kaunitz, MD
, Professor and Associate Chairman, Department of Obstetrics & Gynecology, University of Florida College of Medicine–Jacksonville, Jacksonville, Florida. Dr. Kaunitz serves on the OBG Management Board of Editors.

Author and Disclosure Information

EXPERT COMMENTARY
Andrew M. Kaunitz, MD
, Professor and Associate Chairman, Department of Obstetrics & Gynecology, University of Florida College of Medicine–Jacksonville, Jacksonville, Florida. Dr. Kaunitz serves on the OBG Management Board of Editors.

Article PDF
Article PDF
Related Articles

During the 1990s, more than 90% of hysterectomized women aged 50 to 59 years used ET following the procedure. When the initial findings of the WHI were published in 2002, they prompted many women to refuse or discontinue ET—despite the fact that the initial findings concerned the use of estrogen and progestin in combination in women with an intact uterus. Today, only some 30% of women use ET after hysterectomy.

When findings from the WHI estrogen-only arm were eventually published, they revealed that ET reduces mortality among women 50 to 59 years old, compared with placebo. Although most of the reduction in mortality relates to fewer deaths from coronary heart disease, a decline in deaths from breast cancer also was seen.2,3

Sarrel and colleagues calculated the excess mortality among US women aged 50 to 59 that could have been prevented by ET during the decade from 2002 through 2011. Their estimates ranged from approximately 19,000 deaths to as many as 92,000 deaths.

By calling attention to the negative health consequences of estrogen avoidance in young hysterectomized women, Sarrel and colleagues have performed a valuable public service.

Plethora of WHI data may have contributed to confusion

The WHI clinical trials have produced numerous analyses in various subsets of women. The sheer volume of data may be daunting in some cases, and likely has led to a failure to distinguish between estrogen-only and estrogen-progestin therapy, which have very different safety profiles.

Further, some clinicians and many patients have overlooked the fact that the risk-benefit profile of hormone therapy (both estrogen-only and estrogen-progestin therapy) is more favorable in younger, recently menopausal women than it is in older women.

I encounter evidence of this unwarranted fear of ET in my practice, with highly symptomatic, recently menopausal women who are appropriate candidates for hormone therapy electing to refuse the most effective treatment for menopausal symptoms.

Of course, hormone therapy, like all medications, has risks as well as benefits. For example, oral ET increases the risk of venous thrombosis and stroke, and long-term use of estrogen-progestin therapy increases the risk of breast cancer. However, the overblown fears of estrogen therapy have caused many appropriate candidates to miss out on symptom relief, prevention of osteoporosis, and treatment of symptomatic genital atrophy.

What this evidence means for practice
This provocative report demonstrates that wholesale avoidance of hormone therapy can have important negative public health consequence.
--Andrew M. Kaunitz, MD

We want to hear from you! Tell us what you think.

During the 1990s, more than 90% of hysterectomized women aged 50 to 59 years used ET following the procedure. When the initial findings of the WHI were published in 2002, they prompted many women to refuse or discontinue ET—despite the fact that the initial findings concerned the use of estrogen and progestin in combination in women with an intact uterus. Today, only some 30% of women use ET after hysterectomy.

When findings from the WHI estrogen-only arm were eventually published, they revealed that ET reduces mortality among women 50 to 59 years old, compared with placebo. Although most of the reduction in mortality relates to fewer deaths from coronary heart disease, a decline in deaths from breast cancer also was seen.2,3

Sarrel and colleagues calculated the excess mortality among US women aged 50 to 59 that could have been prevented by ET during the decade from 2002 through 2011. Their estimates ranged from approximately 19,000 deaths to as many as 92,000 deaths.

By calling attention to the negative health consequences of estrogen avoidance in young hysterectomized women, Sarrel and colleagues have performed a valuable public service.

Plethora of WHI data may have contributed to confusion

The WHI clinical trials have produced numerous analyses in various subsets of women. The sheer volume of data may be daunting in some cases, and likely has led to a failure to distinguish between estrogen-only and estrogen-progestin therapy, which have very different safety profiles.

Further, some clinicians and many patients have overlooked the fact that the risk-benefit profile of hormone therapy (both estrogen-only and estrogen-progestin therapy) is more favorable in younger, recently menopausal women than it is in older women.

I encounter evidence of this unwarranted fear of ET in my practice, with highly symptomatic, recently menopausal women who are appropriate candidates for hormone therapy electing to refuse the most effective treatment for menopausal symptoms.

Of course, hormone therapy, like all medications, has risks as well as benefits. For example, oral ET increases the risk of venous thrombosis and stroke, and long-term use of estrogen-progestin therapy increases the risk of breast cancer. However, the overblown fears of estrogen therapy have caused many appropriate candidates to miss out on symptom relief, prevention of osteoporosis, and treatment of symptomatic genital atrophy.

What this evidence means for practice
This provocative report demonstrates that wholesale avoidance of hormone therapy can have important negative public health consequence.
--Andrew M. Kaunitz, MD

We want to hear from you! Tell us what you think.

References

1. Rossouw JE, Anderson GL, Prentice RL, et al; Writing Group for the Women’s Health Initiative Investigators. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results From the Women’s Health Initiative randomized controlled trial. JAMA. 2002;288(3):321–333.

2. LaCroix AZ, Chlebowski RT, Manson JE, et al; WHI Investigators. Health outcomes after stopping conjugated equine estrogens among postmenopausal women with prior hysterectomy: a randomized controlled trial. JAMA. 2011;305(13):1305–1314.

3. Anderson GL, Chlebowski RI, Aragaki AK, et al. Conjugated equine estrogen and breast cancer incidence and mortality in postmenopausal women with hysterectomy: extended follow-up of the Women’s Health Initiative randomized placebo-controlled trial. Lancet Oncol. 2012; 13(5):476–486.

References

1. Rossouw JE, Anderson GL, Prentice RL, et al; Writing Group for the Women’s Health Initiative Investigators. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results From the Women’s Health Initiative randomized controlled trial. JAMA. 2002;288(3):321–333.

2. LaCroix AZ, Chlebowski RT, Manson JE, et al; WHI Investigators. Health outcomes after stopping conjugated equine estrogens among postmenopausal women with prior hysterectomy: a randomized controlled trial. JAMA. 2011;305(13):1305–1314.

3. Anderson GL, Chlebowski RI, Aragaki AK, et al. Conjugated equine estrogen and breast cancer incidence and mortality in postmenopausal women with hysterectomy: extended follow-up of the Women’s Health Initiative randomized placebo-controlled trial. Lancet Oncol. 2012; 13(5):476–486.

Issue
OBG Management - 25(10)
Issue
OBG Management - 25(10)
Page Number
55-56
Page Number
55-56
Publications
Publications
Topics
Article Type
Display Headline
In young hysterectomized women, does unopposed estrogen therapy increase overall survival?
Display Headline
In young hysterectomized women, does unopposed estrogen therapy increase overall survival?
Legacy Keywords
survival, In young hysterectomized women, does unopposed estrogen therapy increase overall survival?, unopposed estrogen therapy, estrogen therapy, ET, unopposed ET, hysterectomy, younger age, young women, hysterectomy, WHI, women's health initiative, preventable death, Andrew M. Kaunitz MD
Legacy Keywords
survival, In young hysterectomized women, does unopposed estrogen therapy increase overall survival?, unopposed estrogen therapy, estrogen therapy, ET, unopposed ET, hysterectomy, younger age, young women, hysterectomy, WHI, women's health initiative, preventable death, Andrew M. Kaunitz MD
Sections
Article Source

PURLs Copyright

Inside the Article

Article PDF Media

MGMA Surveys Make Hospitalists' Productivity Hard to Assess

Article Type
Changed
Fri, 09/14/2018 - 12:16
Display Headline
MGMA Surveys Make Hospitalists' Productivity Hard to Assess

Extra shifts are sometimes even required by the practice to make up for open positions. And in some places, the hospitalists choose not to fill positions to preserve their ability to continue working more than the number of shifts required to be full time.

SHM and MGMA Survey History

SHM’s State of Hospital Medicine reports for 2010, 2011, and 2012 incorporated MGMA data with its limit of 1.0 FTE per doctor, even for doctors who worked many extra shifts. But SHM surveys prior to 2010 provided for a single doctor to be assigned more than 1.0 FTE. For example, a doctor working 20% more shifts than what a practice defined as full time would have gone into those surveys as 1.2 FTE.

The Medical Group Management Association (MGMA) surveys regard both a doctor who works the standard number of annual shifts their practice defines as full time, and a doctor who works many extra shifts, as one full-time equivalent (FTE). This can cause confusion when assessing productivity per FTE (see “SHM and MGMA Survey History,” right).

For example, consider a hospitalist who generated 4,000 wRVUs while working 182 shifts—the standard number of shifts to be full time in that doctor’s practice—during the survey year. In the same practice, another hospitalist worked 39 extra shifts over the same year for a total of 220 shifts, generating 4,860 wRVUs. If the survey contained only these two doctors, it would show them both as full time, with an average productivity per FTE of 4,430 wRVUs. But that would be misleading because 1.0 FTE worth of work as defined by their practice for both doctors would have come to 4,000 wRVUs generated while working 182 shifts.

In prior columns, I’ve highlighted some other numbers in hospitalist productivity and compensation surveys that can lead to confusion. But the MGMA survey methodology, which assigns a particular FTE to a single doctor, may be the most confusing issue, potentially leading to meaningful misunderstandings.

More Details on FTE Definition

MGMA has been conducting physician compensation and productivity surveys across essentially all medical specialties for decades. Competing organizations conduct similar surveys, but most regard the MGMA survey as the most relevant and valuable.

For a long time, MGMA has regarded as “full time” any doctor working 0.75 FTE or greater, using the respondent practice’s definition of an FTE. No single doctor can ever be counted as more than 1.0 FTE, regardless of how much extra the doctor may have worked. Any doctor working 0.35-0.75 FTE is regarded as part time, and those working less than 0.35 FTE are excluded from the survey report. The fact that each practice might have a different definition of what constitutes an FTE is addressed by having a large number of respondents in most medical specialties.

I’m uncertain how MGMA ended up not counting any single doctor as more than 1.0 FTE, even when they work a lot of extra shifts. But my guess is that for the first years, or even decades, that MGMA conducted its survey, few, if any, medical practices even had a strict definition of what constituted 1.0 FTE and simply didn’t keep track of which doctors worked extra shifts or days. So even if MGMA had wanted to know, for example, when a doctor worked extra shifts and should be counted as more than 1.0 FTE, few if any practices even thought about the precise number of shifts or days worked constituting full time versus what was an “extra” shift. So it probably made sense to simply have two categories: full time and part time.

 

 

As more practices began assigning FTE with greater precision, like nearly all hospitalist practices do, then using 0.75 FTE to separate full time and part time seemed practical, though imprecise. But keep in mind it also means that all of the doctors who work from 0.75 to 0.99 FTE (that is, something less than 1.0) offset, at least partially, those who work lots of extra shifts (i.e., above 1.0 FTE).

Data Application

My anecdotal experience is that a large portion of hospitalists, probably around half, work more shifts than what their practice regards as full time. I don’t know of any survey database that quantifies this, but my guess is that 25% to 35% of full-time hospitalists work extra shifts at their own practice, and maybe another 15% to 20% moonlight at a different practice. Let’s consider only those in the first category.

Chronic staffing shortages is one of the reasons hospitalists so commonly work extra shifts at their own practice. Extra shifts are sometimes even required by the practice to make up for open positions. And in some places, the hospitalists choose not to fill positions to preserve their ability to continue working more than the number of shifts required to be full time.

It would be great if we had a precise way to adjust the MGMA survey data for hospitalists who work above 1.0 FTE. For example, let’s make three assumptions so that we can then adjust the reported compensation and productivity data to remove the effect of the many doctors working extra shifts, thereby more clearly matching 1.0 FTE. These numbers are my guesses based on lots of anecdotal experience. But they are only guesses. Don’t make too much of them.

Assume 25% of hospitalists nationally work an average of 20% more than the full-time number of shifts for their practice. That is my best guess and intentionally leaves out those who moonlight for a practice other than their own.

Some portion of those working extra shifts (above 1.0 FTE) is offset by survey respondents working between 0.75 and 1.0 FTE, resulting in a wild guess of a net 20% of hospitalists working extra shifts.

Last, let’s assume that their productivity and compensation on extra shifts is identical to their “normal” shifts. This is not true for many practices, but when aggregating the data, it is probably reasonably close.

Using these assumptions (guesses, really), we can decrease both the reported survey mean and median productivity and compensation by about 5% to more accurately reflect results for hospitalists doing only the number of shifts required by the practice to be full time—no extra shifts. I’ll spare you the simple math showing how I arrived at the approximately 5%, but basically it is removing the 20% additional compensation and productivity generated by the net 20% of hospitalists who work extra shifts above 1.0 FTE.

Does It Really Matter?

The whole issue of hospitalists working many extra shifts yet only counting as 1.0 FTE in the MGMA survey might matter a lot for some, and others might see it as useless hand-wringing. As long as a meaningful number of hospitalists work extra shifts, then survey values for productivity and compensation will always be a little higher than the “average” 1.0 FTE hospitalists working no extra shifts. But it may still be well within the range of error of the survey anyway. And the compensation per unit of work (wRVUs or encounters) probably isn’t much affected by this FTE issue.


Dr. Nelson has been a practicing hospitalist since 1988. He is co-founder and past president of SHM, and principal in Nelson Flores Hospital Medicine Consultants. He is co-director for SHM’s “Best Practices in Managing a Hospital Medicine Program” course. Write to him at [email protected].

Issue
The Hospitalist - 2013(10)
Publications
Sections

Extra shifts are sometimes even required by the practice to make up for open positions. And in some places, the hospitalists choose not to fill positions to preserve their ability to continue working more than the number of shifts required to be full time.

SHM and MGMA Survey History

SHM’s State of Hospital Medicine reports for 2010, 2011, and 2012 incorporated MGMA data with its limit of 1.0 FTE per doctor, even for doctors who worked many extra shifts. But SHM surveys prior to 2010 provided for a single doctor to be assigned more than 1.0 FTE. For example, a doctor working 20% more shifts than what a practice defined as full time would have gone into those surveys as 1.2 FTE.

The Medical Group Management Association (MGMA) surveys regard both a doctor who works the standard number of annual shifts their practice defines as full time, and a doctor who works many extra shifts, as one full-time equivalent (FTE). This can cause confusion when assessing productivity per FTE (see “SHM and MGMA Survey History,” right).

For example, consider a hospitalist who generated 4,000 wRVUs while working 182 shifts—the standard number of shifts to be full time in that doctor’s practice—during the survey year. In the same practice, another hospitalist worked 39 extra shifts over the same year for a total of 220 shifts, generating 4,860 wRVUs. If the survey contained only these two doctors, it would show them both as full time, with an average productivity per FTE of 4,430 wRVUs. But that would be misleading because 1.0 FTE worth of work as defined by their practice for both doctors would have come to 4,000 wRVUs generated while working 182 shifts.

In prior columns, I’ve highlighted some other numbers in hospitalist productivity and compensation surveys that can lead to confusion. But the MGMA survey methodology, which assigns a particular FTE to a single doctor, may be the most confusing issue, potentially leading to meaningful misunderstandings.

More Details on FTE Definition

MGMA has been conducting physician compensation and productivity surveys across essentially all medical specialties for decades. Competing organizations conduct similar surveys, but most regard the MGMA survey as the most relevant and valuable.

For a long time, MGMA has regarded as “full time” any doctor working 0.75 FTE or greater, using the respondent practice’s definition of an FTE. No single doctor can ever be counted as more than 1.0 FTE, regardless of how much extra the doctor may have worked. Any doctor working 0.35-0.75 FTE is regarded as part time, and those working less than 0.35 FTE are excluded from the survey report. The fact that each practice might have a different definition of what constitutes an FTE is addressed by having a large number of respondents in most medical specialties.

I’m uncertain how MGMA ended up not counting any single doctor as more than 1.0 FTE, even when they work a lot of extra shifts. But my guess is that for the first years, or even decades, that MGMA conducted its survey, few, if any, medical practices even had a strict definition of what constituted 1.0 FTE and simply didn’t keep track of which doctors worked extra shifts or days. So even if MGMA had wanted to know, for example, when a doctor worked extra shifts and should be counted as more than 1.0 FTE, few if any practices even thought about the precise number of shifts or days worked constituting full time versus what was an “extra” shift. So it probably made sense to simply have two categories: full time and part time.

 

 

As more practices began assigning FTE with greater precision, like nearly all hospitalist practices do, then using 0.75 FTE to separate full time and part time seemed practical, though imprecise. But keep in mind it also means that all of the doctors who work from 0.75 to 0.99 FTE (that is, something less than 1.0) offset, at least partially, those who work lots of extra shifts (i.e., above 1.0 FTE).

Data Application

My anecdotal experience is that a large portion of hospitalists, probably around half, work more shifts than what their practice regards as full time. I don’t know of any survey database that quantifies this, but my guess is that 25% to 35% of full-time hospitalists work extra shifts at their own practice, and maybe another 15% to 20% moonlight at a different practice. Let’s consider only those in the first category.

Chronic staffing shortages is one of the reasons hospitalists so commonly work extra shifts at their own practice. Extra shifts are sometimes even required by the practice to make up for open positions. And in some places, the hospitalists choose not to fill positions to preserve their ability to continue working more than the number of shifts required to be full time.

It would be great if we had a precise way to adjust the MGMA survey data for hospitalists who work above 1.0 FTE. For example, let’s make three assumptions so that we can then adjust the reported compensation and productivity data to remove the effect of the many doctors working extra shifts, thereby more clearly matching 1.0 FTE. These numbers are my guesses based on lots of anecdotal experience. But they are only guesses. Don’t make too much of them.

Assume 25% of hospitalists nationally work an average of 20% more than the full-time number of shifts for their practice. That is my best guess and intentionally leaves out those who moonlight for a practice other than their own.

Some portion of those working extra shifts (above 1.0 FTE) is offset by survey respondents working between 0.75 and 1.0 FTE, resulting in a wild guess of a net 20% of hospitalists working extra shifts.

Last, let’s assume that their productivity and compensation on extra shifts is identical to their “normal” shifts. This is not true for many practices, but when aggregating the data, it is probably reasonably close.

Using these assumptions (guesses, really), we can decrease both the reported survey mean and median productivity and compensation by about 5% to more accurately reflect results for hospitalists doing only the number of shifts required by the practice to be full time—no extra shifts. I’ll spare you the simple math showing how I arrived at the approximately 5%, but basically it is removing the 20% additional compensation and productivity generated by the net 20% of hospitalists who work extra shifts above 1.0 FTE.

Does It Really Matter?

The whole issue of hospitalists working many extra shifts yet only counting as 1.0 FTE in the MGMA survey might matter a lot for some, and others might see it as useless hand-wringing. As long as a meaningful number of hospitalists work extra shifts, then survey values for productivity and compensation will always be a little higher than the “average” 1.0 FTE hospitalists working no extra shifts. But it may still be well within the range of error of the survey anyway. And the compensation per unit of work (wRVUs or encounters) probably isn’t much affected by this FTE issue.


Dr. Nelson has been a practicing hospitalist since 1988. He is co-founder and past president of SHM, and principal in Nelson Flores Hospital Medicine Consultants. He is co-director for SHM’s “Best Practices in Managing a Hospital Medicine Program” course. Write to him at [email protected].

Extra shifts are sometimes even required by the practice to make up for open positions. And in some places, the hospitalists choose not to fill positions to preserve their ability to continue working more than the number of shifts required to be full time.

SHM and MGMA Survey History

SHM’s State of Hospital Medicine reports for 2010, 2011, and 2012 incorporated MGMA data with its limit of 1.0 FTE per doctor, even for doctors who worked many extra shifts. But SHM surveys prior to 2010 provided for a single doctor to be assigned more than 1.0 FTE. For example, a doctor working 20% more shifts than what a practice defined as full time would have gone into those surveys as 1.2 FTE.

The Medical Group Management Association (MGMA) surveys regard both a doctor who works the standard number of annual shifts their practice defines as full time, and a doctor who works many extra shifts, as one full-time equivalent (FTE). This can cause confusion when assessing productivity per FTE (see “SHM and MGMA Survey History,” right).

For example, consider a hospitalist who generated 4,000 wRVUs while working 182 shifts—the standard number of shifts to be full time in that doctor’s practice—during the survey year. In the same practice, another hospitalist worked 39 extra shifts over the same year for a total of 220 shifts, generating 4,860 wRVUs. If the survey contained only these two doctors, it would show them both as full time, with an average productivity per FTE of 4,430 wRVUs. But that would be misleading because 1.0 FTE worth of work as defined by their practice for both doctors would have come to 4,000 wRVUs generated while working 182 shifts.

In prior columns, I’ve highlighted some other numbers in hospitalist productivity and compensation surveys that can lead to confusion. But the MGMA survey methodology, which assigns a particular FTE to a single doctor, may be the most confusing issue, potentially leading to meaningful misunderstandings.

More Details on FTE Definition

MGMA has been conducting physician compensation and productivity surveys across essentially all medical specialties for decades. Competing organizations conduct similar surveys, but most regard the MGMA survey as the most relevant and valuable.

For a long time, MGMA has regarded as “full time” any doctor working 0.75 FTE or greater, using the respondent practice’s definition of an FTE. No single doctor can ever be counted as more than 1.0 FTE, regardless of how much extra the doctor may have worked. Any doctor working 0.35-0.75 FTE is regarded as part time, and those working less than 0.35 FTE are excluded from the survey report. The fact that each practice might have a different definition of what constitutes an FTE is addressed by having a large number of respondents in most medical specialties.

I’m uncertain how MGMA ended up not counting any single doctor as more than 1.0 FTE, even when they work a lot of extra shifts. But my guess is that for the first years, or even decades, that MGMA conducted its survey, few, if any, medical practices even had a strict definition of what constituted 1.0 FTE and simply didn’t keep track of which doctors worked extra shifts or days. So even if MGMA had wanted to know, for example, when a doctor worked extra shifts and should be counted as more than 1.0 FTE, few if any practices even thought about the precise number of shifts or days worked constituting full time versus what was an “extra” shift. So it probably made sense to simply have two categories: full time and part time.

 

 

As more practices began assigning FTE with greater precision, like nearly all hospitalist practices do, then using 0.75 FTE to separate full time and part time seemed practical, though imprecise. But keep in mind it also means that all of the doctors who work from 0.75 to 0.99 FTE (that is, something less than 1.0) offset, at least partially, those who work lots of extra shifts (i.e., above 1.0 FTE).

Data Application

My anecdotal experience is that a large portion of hospitalists, probably around half, work more shifts than what their practice regards as full time. I don’t know of any survey database that quantifies this, but my guess is that 25% to 35% of full-time hospitalists work extra shifts at their own practice, and maybe another 15% to 20% moonlight at a different practice. Let’s consider only those in the first category.

Chronic staffing shortages is one of the reasons hospitalists so commonly work extra shifts at their own practice. Extra shifts are sometimes even required by the practice to make up for open positions. And in some places, the hospitalists choose not to fill positions to preserve their ability to continue working more than the number of shifts required to be full time.

It would be great if we had a precise way to adjust the MGMA survey data for hospitalists who work above 1.0 FTE. For example, let’s make three assumptions so that we can then adjust the reported compensation and productivity data to remove the effect of the many doctors working extra shifts, thereby more clearly matching 1.0 FTE. These numbers are my guesses based on lots of anecdotal experience. But they are only guesses. Don’t make too much of them.

Assume 25% of hospitalists nationally work an average of 20% more than the full-time number of shifts for their practice. That is my best guess and intentionally leaves out those who moonlight for a practice other than their own.

Some portion of those working extra shifts (above 1.0 FTE) is offset by survey respondents working between 0.75 and 1.0 FTE, resulting in a wild guess of a net 20% of hospitalists working extra shifts.

Last, let’s assume that their productivity and compensation on extra shifts is identical to their “normal” shifts. This is not true for many practices, but when aggregating the data, it is probably reasonably close.

Using these assumptions (guesses, really), we can decrease both the reported survey mean and median productivity and compensation by about 5% to more accurately reflect results for hospitalists doing only the number of shifts required by the practice to be full time—no extra shifts. I’ll spare you the simple math showing how I arrived at the approximately 5%, but basically it is removing the 20% additional compensation and productivity generated by the net 20% of hospitalists who work extra shifts above 1.0 FTE.

Does It Really Matter?

The whole issue of hospitalists working many extra shifts yet only counting as 1.0 FTE in the MGMA survey might matter a lot for some, and others might see it as useless hand-wringing. As long as a meaningful number of hospitalists work extra shifts, then survey values for productivity and compensation will always be a little higher than the “average” 1.0 FTE hospitalists working no extra shifts. But it may still be well within the range of error of the survey anyway. And the compensation per unit of work (wRVUs or encounters) probably isn’t much affected by this FTE issue.


Dr. Nelson has been a practicing hospitalist since 1988. He is co-founder and past president of SHM, and principal in Nelson Flores Hospital Medicine Consultants. He is co-director for SHM’s “Best Practices in Managing a Hospital Medicine Program” course. Write to him at [email protected].

Issue
The Hospitalist - 2013(10)
Issue
The Hospitalist - 2013(10)
Publications
Publications
Article Type
Display Headline
MGMA Surveys Make Hospitalists' Productivity Hard to Assess
Display Headline
MGMA Surveys Make Hospitalists' Productivity Hard to Assess
Sections
Disallow All Ads
Content Gating
No Gating (article Unlocked/Free)

New Rules for Value-Based Purchasing, Readmission Penalties, Admissions

Article Type
Changed
Fri, 09/14/2018 - 12:16
Display Headline
New Rules for Value-Based Purchasing, Readmission Penalties, Admissions

The View from

Looking for more information to formulate a plan of attack? SHM offers a variety of HVBP resources to orient hospitalists and hospital leaders. The “What Every Hospitalist Should Know About Hospital Value-Based Purchasing” webinar and SHM’s free resource library (www.hospitalmedicine.org/hvbp) offer basic orientation on what to expect on pay-for-performance-related issues. The HVBP resource center also provides multiple case studies from various hospitals across the country, with success stories related to reducing readmissions, increasing evidence-based care focus, and enhancing performance on core measures.

In order to proactively address CMS’ new 30-day readmissions criteria for COPD, SHM’s COPD Resource Center (www.hospitalmedicine.org/copd) provides hospitalists with the most up-to-date guidelines, reviews, and peer-reviewed clinical trials that define evidence-based practice for the care of the COPD patient.

Hospitalists not only are under pressure to help improve hospital-level performance, but also will need to begin reporting physician-level measures. Beginning in 2015, CMS’s Physician Quality Reporting System (PQRS) will apply a penalty to all physicians who do not satisfactorily report data on quality measures for covered professional services.

The time to act is now. Reporting during the 2013 PQRS program year will be used to determine whether a 1.5% penalty applies in 2015. SHM has partnered with CECity to offer discounted access to PQRIwizard, a tool that facilitates PQRS reporting through SHM’s Learning Portal (www.shmlearningportal.org).

October is the beginning of a new year—in this case, fiscal-year 2014 for the Centers for Medicare & Medicaid Services (CMS). It’s a time when the new rules kick in. This month, we’ll look at some highlights, focusing on the new developments affecting your practice. Because you are held accountable for hospital-side performance on programs such as hospital value-based purchasing (HVBP) and the Readmissions Reduction Program, a working knowledge of the 2014 edition of the programs is crucial.

Close the Loop on HVBP

How will your hospital get paid under the 2014 version of HVBP? This past July, your hospital received a report outlining how its Medicare payments will be affected based on your hospital’s performance on process of care (heart failure, pneumonia, myocardial infarction, and surgery), patient experience (HCAHPS), and outcomes (30-day mortality for heart failure, pneumonia, and myocardial infarction).

Here are two hypothetical hospitals and how their performance in the program affects their 2014 payment. As background, in 2014, all hospitals have their base diagnosis related group (DRG) payments reduced by 1.25% for HVBP. They can earn back some, all, or an amount in excess of the 1.25% based on their performance. Payment is based on performance during the April 1 to Dec. 31, 2012, period. Under HVBP, CMS incentive payments occur at the level of individual patients, each of which is assigned a DRG.

Let’s look at two examples:

Hospital 1

  • Base DRG payment reduction: 1.25% (all hospitals).
  • Portion of base DRG earned back based on performance (process/patient experience/outcome metrics): 1.48%.
  • Net change in base DRG payment: +0.23%.

Hospital 2

  • Base DRG payment reduction: 1.25% (all hospitals).
  • Portion of base DRG earned back based on performance (process/patient experience/outcome metrics): 1.08%.
  • Net change in base DRG payment: -0.17%.

Hospital 1 performed relatively well, getting a bump of 0.23% in its base DRG rate. Hospital 2 did not perform so well, so it took a 0.17% hit on its base DRG rate.

In order to determine total dollars made or lost for your hospital, one multiplies the total number of eligible Medicare inpatients for 2014 times the base DRG payment times the percent change in base DRG payment. If Hospital 1 has 10,000 eligible patients in 2014 and a base DRG payment of $5,000, the value is 10,000 x $5,000 x 0.0023 (0.23%) = $115,000 gained. Hospital 2, with the same number of patients and base DRG payment, loses (10,000 x $5,000 x 0.0017 = $85,000).

 

 

Readmissions and Penalties

For 2014, CMS is adding 30-day readmissions for COPD to readmissions for heart failure, pneumonia, and myocardial infarction for its penalty program. CMS added COPD because it is the fourth-leading cause of readmissions, according to a recent Medicare Payment Advisory Commission report, and because there is wide variation in the rates (from 18% to 25%) of COPD hospital readmissions.

For 2014, CMS raises the ceiling on readmission penalties to a maximum of 2% of reimbursement for all of a hospital’s Medicare inpatients. (The maximum hit during the first round of readmission penalties, which began in October 2012, was 1%.) More than 2,200 U.S. hospitals will face some financial penalty for excess 30-day readmissions.

Disappointingly, CMS did not add a risk adjustment for socioeconomic status despite being under pressure to do so. There is growing evidence that these factors have a major impact on readmission rates.1,2

New Definition of an Admission

Amidst confusion from many and major blowback from beneficiaries saddled with large out-of-pocket expenses for observation stays and subsequent skilled-nursing-facility stays, CMS is clarifying the definition of an inpatient admission. The agency will define an admission as a hospital stay that spans at least two midnights. If a patient is in the hospital for a shorter period of time, CMS will deem the patient to be on observation status, unless medical record documentation supports a physician’s expectation “that the beneficiary would need care spanning at least two midnights” but unanticipated events led to a shorter stay.

Plan of Attack

For HVBP, make contact with your director of quality to understand your hospital’s performance and payment for 2014. If you have incentive compensation riding on HVBP, make sure you understand how your employer or contracted hospital is calculating the payout (because, for example, the performance period was in 2012!) and that your hospitalist group understands the payout calculation.

For COPD readmissions prevention, ensure patients have a home management plan; appropriate specialist follow-up and that they understand medication use, including inhalers and supplemental oxygen; and that you consider early referral for pulmonary rehabilitation for eligible patients.

For the new definition of inpatient admission, work with your hospital’s physician advisor and case management to ensure your group is getting appropriate guidance on documentation requirements. You are probably being held accountable for your hospital’s total number of observation hours, so remember to track these metrics following implementation of the new rule, as they (hopefully) should decrease. If they do, take some of the credit!

References

  1. Joynt KE, Orav EJ, Jha AK. Thirty-day readmission rates for Medicare beneficiaries by race and site of care. JAMA. 2011;305(7):675-681.
  2. Lindenauer PK, Lagu T, Rothberg MB, et al. Income inequality and 30 day outcomes after acute myocardial infarction, heart failure, and pneumonia: retrospective cohort study. BMJ. 2013;346:f521.


Dr. Whitcomb is medical director of healthcare quality at Baystate Medical Center in Springfield, Mass. He is co-founder and past president of SHM. Email him at [email protected].

Issue
The Hospitalist - 2013(10)
Publications
Sections

The View from

Looking for more information to formulate a plan of attack? SHM offers a variety of HVBP resources to orient hospitalists and hospital leaders. The “What Every Hospitalist Should Know About Hospital Value-Based Purchasing” webinar and SHM’s free resource library (www.hospitalmedicine.org/hvbp) offer basic orientation on what to expect on pay-for-performance-related issues. The HVBP resource center also provides multiple case studies from various hospitals across the country, with success stories related to reducing readmissions, increasing evidence-based care focus, and enhancing performance on core measures.

In order to proactively address CMS’ new 30-day readmissions criteria for COPD, SHM’s COPD Resource Center (www.hospitalmedicine.org/copd) provides hospitalists with the most up-to-date guidelines, reviews, and peer-reviewed clinical trials that define evidence-based practice for the care of the COPD patient.

Hospitalists not only are under pressure to help improve hospital-level performance, but also will need to begin reporting physician-level measures. Beginning in 2015, CMS’s Physician Quality Reporting System (PQRS) will apply a penalty to all physicians who do not satisfactorily report data on quality measures for covered professional services.

The time to act is now. Reporting during the 2013 PQRS program year will be used to determine whether a 1.5% penalty applies in 2015. SHM has partnered with CECity to offer discounted access to PQRIwizard, a tool that facilitates PQRS reporting through SHM’s Learning Portal (www.shmlearningportal.org).

October is the beginning of a new year—in this case, fiscal-year 2014 for the Centers for Medicare & Medicaid Services (CMS). It’s a time when the new rules kick in. This month, we’ll look at some highlights, focusing on the new developments affecting your practice. Because you are held accountable for hospital-side performance on programs such as hospital value-based purchasing (HVBP) and the Readmissions Reduction Program, a working knowledge of the 2014 edition of the programs is crucial.

Close the Loop on HVBP

How will your hospital get paid under the 2014 version of HVBP? This past July, your hospital received a report outlining how its Medicare payments will be affected based on your hospital’s performance on process of care (heart failure, pneumonia, myocardial infarction, and surgery), patient experience (HCAHPS), and outcomes (30-day mortality for heart failure, pneumonia, and myocardial infarction).

Here are two hypothetical hospitals and how their performance in the program affects their 2014 payment. As background, in 2014, all hospitals have their base diagnosis related group (DRG) payments reduced by 1.25% for HVBP. They can earn back some, all, or an amount in excess of the 1.25% based on their performance. Payment is based on performance during the April 1 to Dec. 31, 2012, period. Under HVBP, CMS incentive payments occur at the level of individual patients, each of which is assigned a DRG.

Let’s look at two examples:

Hospital 1

  • Base DRG payment reduction: 1.25% (all hospitals).
  • Portion of base DRG earned back based on performance (process/patient experience/outcome metrics): 1.48%.
  • Net change in base DRG payment: +0.23%.

Hospital 2

  • Base DRG payment reduction: 1.25% (all hospitals).
  • Portion of base DRG earned back based on performance (process/patient experience/outcome metrics): 1.08%.
  • Net change in base DRG payment: -0.17%.

Hospital 1 performed relatively well, getting a bump of 0.23% in its base DRG rate. Hospital 2 did not perform so well, so it took a 0.17% hit on its base DRG rate.

In order to determine total dollars made or lost for your hospital, one multiplies the total number of eligible Medicare inpatients for 2014 times the base DRG payment times the percent change in base DRG payment. If Hospital 1 has 10,000 eligible patients in 2014 and a base DRG payment of $5,000, the value is 10,000 x $5,000 x 0.0023 (0.23%) = $115,000 gained. Hospital 2, with the same number of patients and base DRG payment, loses (10,000 x $5,000 x 0.0017 = $85,000).

 

 

Readmissions and Penalties

For 2014, CMS is adding 30-day readmissions for COPD to readmissions for heart failure, pneumonia, and myocardial infarction for its penalty program. CMS added COPD because it is the fourth-leading cause of readmissions, according to a recent Medicare Payment Advisory Commission report, and because there is wide variation in the rates (from 18% to 25%) of COPD hospital readmissions.

For 2014, CMS raises the ceiling on readmission penalties to a maximum of 2% of reimbursement for all of a hospital’s Medicare inpatients. (The maximum hit during the first round of readmission penalties, which began in October 2012, was 1%.) More than 2,200 U.S. hospitals will face some financial penalty for excess 30-day readmissions.

Disappointingly, CMS did not add a risk adjustment for socioeconomic status despite being under pressure to do so. There is growing evidence that these factors have a major impact on readmission rates.1,2

New Definition of an Admission

Amidst confusion from many and major blowback from beneficiaries saddled with large out-of-pocket expenses for observation stays and subsequent skilled-nursing-facility stays, CMS is clarifying the definition of an inpatient admission. The agency will define an admission as a hospital stay that spans at least two midnights. If a patient is in the hospital for a shorter period of time, CMS will deem the patient to be on observation status, unless medical record documentation supports a physician’s expectation “that the beneficiary would need care spanning at least two midnights” but unanticipated events led to a shorter stay.

Plan of Attack

For HVBP, make contact with your director of quality to understand your hospital’s performance and payment for 2014. If you have incentive compensation riding on HVBP, make sure you understand how your employer or contracted hospital is calculating the payout (because, for example, the performance period was in 2012!) and that your hospitalist group understands the payout calculation.

For COPD readmissions prevention, ensure patients have a home management plan; appropriate specialist follow-up and that they understand medication use, including inhalers and supplemental oxygen; and that you consider early referral for pulmonary rehabilitation for eligible patients.

For the new definition of inpatient admission, work with your hospital’s physician advisor and case management to ensure your group is getting appropriate guidance on documentation requirements. You are probably being held accountable for your hospital’s total number of observation hours, so remember to track these metrics following implementation of the new rule, as they (hopefully) should decrease. If they do, take some of the credit!

References

  1. Joynt KE, Orav EJ, Jha AK. Thirty-day readmission rates for Medicare beneficiaries by race and site of care. JAMA. 2011;305(7):675-681.
  2. Lindenauer PK, Lagu T, Rothberg MB, et al. Income inequality and 30 day outcomes after acute myocardial infarction, heart failure, and pneumonia: retrospective cohort study. BMJ. 2013;346:f521.


Dr. Whitcomb is medical director of healthcare quality at Baystate Medical Center in Springfield, Mass. He is co-founder and past president of SHM. Email him at [email protected].

The View from

Looking for more information to formulate a plan of attack? SHM offers a variety of HVBP resources to orient hospitalists and hospital leaders. The “What Every Hospitalist Should Know About Hospital Value-Based Purchasing” webinar and SHM’s free resource library (www.hospitalmedicine.org/hvbp) offer basic orientation on what to expect on pay-for-performance-related issues. The HVBP resource center also provides multiple case studies from various hospitals across the country, with success stories related to reducing readmissions, increasing evidence-based care focus, and enhancing performance on core measures.

In order to proactively address CMS’ new 30-day readmissions criteria for COPD, SHM’s COPD Resource Center (www.hospitalmedicine.org/copd) provides hospitalists with the most up-to-date guidelines, reviews, and peer-reviewed clinical trials that define evidence-based practice for the care of the COPD patient.

Hospitalists not only are under pressure to help improve hospital-level performance, but also will need to begin reporting physician-level measures. Beginning in 2015, CMS’s Physician Quality Reporting System (PQRS) will apply a penalty to all physicians who do not satisfactorily report data on quality measures for covered professional services.

The time to act is now. Reporting during the 2013 PQRS program year will be used to determine whether a 1.5% penalty applies in 2015. SHM has partnered with CECity to offer discounted access to PQRIwizard, a tool that facilitates PQRS reporting through SHM’s Learning Portal (www.shmlearningportal.org).

October is the beginning of a new year—in this case, fiscal-year 2014 for the Centers for Medicare & Medicaid Services (CMS). It’s a time when the new rules kick in. This month, we’ll look at some highlights, focusing on the new developments affecting your practice. Because you are held accountable for hospital-side performance on programs such as hospital value-based purchasing (HVBP) and the Readmissions Reduction Program, a working knowledge of the 2014 edition of the programs is crucial.

Close the Loop on HVBP

How will your hospital get paid under the 2014 version of HVBP? This past July, your hospital received a report outlining how its Medicare payments will be affected based on your hospital’s performance on process of care (heart failure, pneumonia, myocardial infarction, and surgery), patient experience (HCAHPS), and outcomes (30-day mortality for heart failure, pneumonia, and myocardial infarction).

Here are two hypothetical hospitals and how their performance in the program affects their 2014 payment. As background, in 2014, all hospitals have their base diagnosis related group (DRG) payments reduced by 1.25% for HVBP. They can earn back some, all, or an amount in excess of the 1.25% based on their performance. Payment is based on performance during the April 1 to Dec. 31, 2012, period. Under HVBP, CMS incentive payments occur at the level of individual patients, each of which is assigned a DRG.

Let’s look at two examples:

Hospital 1

  • Base DRG payment reduction: 1.25% (all hospitals).
  • Portion of base DRG earned back based on performance (process/patient experience/outcome metrics): 1.48%.
  • Net change in base DRG payment: +0.23%.

Hospital 2

  • Base DRG payment reduction: 1.25% (all hospitals).
  • Portion of base DRG earned back based on performance (process/patient experience/outcome metrics): 1.08%.
  • Net change in base DRG payment: -0.17%.

Hospital 1 performed relatively well, getting a bump of 0.23% in its base DRG rate. Hospital 2 did not perform so well, so it took a 0.17% hit on its base DRG rate.

In order to determine total dollars made or lost for your hospital, one multiplies the total number of eligible Medicare inpatients for 2014 times the base DRG payment times the percent change in base DRG payment. If Hospital 1 has 10,000 eligible patients in 2014 and a base DRG payment of $5,000, the value is 10,000 x $5,000 x 0.0023 (0.23%) = $115,000 gained. Hospital 2, with the same number of patients and base DRG payment, loses (10,000 x $5,000 x 0.0017 = $85,000).

 

 

Readmissions and Penalties

For 2014, CMS is adding 30-day readmissions for COPD to readmissions for heart failure, pneumonia, and myocardial infarction for its penalty program. CMS added COPD because it is the fourth-leading cause of readmissions, according to a recent Medicare Payment Advisory Commission report, and because there is wide variation in the rates (from 18% to 25%) of COPD hospital readmissions.

For 2014, CMS raises the ceiling on readmission penalties to a maximum of 2% of reimbursement for all of a hospital’s Medicare inpatients. (The maximum hit during the first round of readmission penalties, which began in October 2012, was 1%.) More than 2,200 U.S. hospitals will face some financial penalty for excess 30-day readmissions.

Disappointingly, CMS did not add a risk adjustment for socioeconomic status despite being under pressure to do so. There is growing evidence that these factors have a major impact on readmission rates.1,2

New Definition of an Admission

Amidst confusion from many and major blowback from beneficiaries saddled with large out-of-pocket expenses for observation stays and subsequent skilled-nursing-facility stays, CMS is clarifying the definition of an inpatient admission. The agency will define an admission as a hospital stay that spans at least two midnights. If a patient is in the hospital for a shorter period of time, CMS will deem the patient to be on observation status, unless medical record documentation supports a physician’s expectation “that the beneficiary would need care spanning at least two midnights” but unanticipated events led to a shorter stay.

Plan of Attack

For HVBP, make contact with your director of quality to understand your hospital’s performance and payment for 2014. If you have incentive compensation riding on HVBP, make sure you understand how your employer or contracted hospital is calculating the payout (because, for example, the performance period was in 2012!) and that your hospitalist group understands the payout calculation.

For COPD readmissions prevention, ensure patients have a home management plan; appropriate specialist follow-up and that they understand medication use, including inhalers and supplemental oxygen; and that you consider early referral for pulmonary rehabilitation for eligible patients.

For the new definition of inpatient admission, work with your hospital’s physician advisor and case management to ensure your group is getting appropriate guidance on documentation requirements. You are probably being held accountable for your hospital’s total number of observation hours, so remember to track these metrics following implementation of the new rule, as they (hopefully) should decrease. If they do, take some of the credit!

References

  1. Joynt KE, Orav EJ, Jha AK. Thirty-day readmission rates for Medicare beneficiaries by race and site of care. JAMA. 2011;305(7):675-681.
  2. Lindenauer PK, Lagu T, Rothberg MB, et al. Income inequality and 30 day outcomes after acute myocardial infarction, heart failure, and pneumonia: retrospective cohort study. BMJ. 2013;346:f521.


Dr. Whitcomb is medical director of healthcare quality at Baystate Medical Center in Springfield, Mass. He is co-founder and past president of SHM. Email him at [email protected].

Issue
The Hospitalist - 2013(10)
Issue
The Hospitalist - 2013(10)
Publications
Publications
Article Type
Display Headline
New Rules for Value-Based Purchasing, Readmission Penalties, Admissions
Display Headline
New Rules for Value-Based Purchasing, Readmission Penalties, Admissions
Sections
Disallow All Ads
Content Gating
No Gating (article Unlocked/Free)

MGMA Physician Compensation Survey Raises Questions About Performance Pay

Article Type
Changed
Fri, 09/14/2018 - 12:17
Display Headline
MGMA Physician Compensation Survey Raises Questions About Performance Pay

Sorting out whether a hospitalist’s bonus and other compensation elements are in line with survey data often leads to confusion. The 2013 MGMA Physician Compensation and Production Survey report, based on 2012 data, shows median compensation of $240,352 for internal-medicine hospitalists (I’ll round it to $240,000 for the rest of this piece). So is your compensation in line with survey medians if your base pay is $230,000 and you have a performance bonus of up to $20,000?

The problem is that you can’t know in advance how much of the $20,000 performance bonus you will earn. And isn’t a bonus supposed to be on top of typical compensation? To be in line with the survey, shouldn’t your base pay equal the $240,000 median, with any available bonus dollars on top of that? (Base pay means all forms of compensation other than a performance bonus; it could be productivity-based compensation, pay connected to numbers of shifts or hours worked, or a fixed annual salary, etc.)

The short answer is no, and to demonstrate why, I’ll first review some facts about the survey itself, then apply that knowledge to the hospitalist marketplace.

I want to emphasize that in this article, I’m not taking a position on the right amount of workload, compensation, or bonus for any hospitalist practice. And I’m using survey medians just to simplify the discussion, not because they’re optimal for any particular practice.

Survey Data

The most important thing to know about the survey data is that the $240,000 figure takes into account all forms of pay, including extra shift pay and any bonuses that might have been paid to each provider in the data set. Such benefits as health insurance and retirement-plan contribution are not included in this figure.

There are several ways a hospitalist might have earned compensation that matches the survey median. He or she might have a fixed annual salary equal to the median with no bonus available or had a meaningful bonus (e.g. $10,000 to $20,000) available and failed to earn any of it. Or the base might have come to $230,000, and he or she earned half of the available $20,000 performance bonus. Many other permutations of bonus and other salary elements could occur to arrive at the same $240,000 figure.

The important thing to remember is that whatever bonus dollars were paid, they are included in the salary figure from the survey—not added on top of that figure. So if all bonus dollars earned were subtracted from the survey, the total “nonbonus” compensation would be lower than $240,000.

How much lower?

If you follow the reasoning above, then you probably agree that if your goal is to match mean compensation from the MGMA survey, then you would set nonbonus compensation 7% below median—as long as you’re likely to get the same portion of a bonus as the median practice.

Typical Hospitalist Bonus Amounts

The MGMA survey doesn’t report the portion of compensation tied to a bonus, but SHM’s does. SHM’s 2012 State of Hospital Medicine Report, based on 2011 data (www.hospitalmedicine.org/survey), is based on the most recent data available, and it showed (on page 60) that an average of 7% of pay was tied to performance for nonacademic hospitalist groups serving adults only. This included any payments for good individual or group performance on quality, efficiency, service, satisfaction, and/or other nonproduction measures. In conversation, this often is referred to as a “bonus” rather than “performance compensation.”

One way to estimate the nonbonus compensation would be to reduce the total pay by 7%, which comes to $223,200. Keep in mind that there are all kinds of mathematical and methodological problems in manipulating the reported survey numbers from two separate surveys to derive additional benchmarks. But this seems like a reasonable guess.

 

 

An increasing portion of hospitalist groups have some pay tied to performance, and the portion of total pay tied to performance seems to be going up at least a little. It was 5% of pay in 2010 and 4% in 2011, compared with 7% in the 2012 survey.

Keep in mind two things. First, this 7% reflects the performance or bonus dollars actually paid out, not the total amount available. In other words, even if the median total bonus dollars available were 20% of compensation, hospitalists earned less than that. Some hospitalists earned all dollars available, and some earned only a portion of what was available. And second, some hospitalists fail to earn any bonus or don’t have one available at all. So the survey would show for them zero compensation tied to bonus.

Making Sense of the Numbers

If you follow the reasoning above, then you probably agree that if your goal is to match mean compensation from the MGMA survey (I’m not suggesting that is the best goal, merely using it for simplicity), then you would set nonbonus compensation 7% below median—as long as you’re likely to get the same portion of a bonus as the median practice.

In some practices, performance thresholds are set at a level that is very easy to achieve, meaning the hospitalists are almost guaranteed to get all of the bonus compensation available. To be consistent with survey medians, it would be appropriate for them to set nonbonus compensation by subtracting all bonus dollars from the survey median. For example, if a $20,000 bonus is available and all of it is likely to be earned by the hospitalists, then total nonbonus compensation would be $220,000.

However, what if the bonus requires significant improvements in performance by the doctors (which seems most appropriate to me; why have a bonus otherwise?) and it is likely they will earn only 25% of all bonus dollars available? If the total available bonus is $20,000, then something like 25%, or $5,000, should be subtracted from the median to yield a total nonbonus compensation of $235,000.

Simple Thinking

I think it makes most sense to set total nonbonus compensation below the targeted total compensation. Failure to achieve any performance thresholds means no bonus and compensation will be below target that year. Meeting some thresholds (some improvement in performance) should result in matching the target compensation, and truly terrific performance that meets or exceeds all thresholds should result in the doctor being paid above the target.


Dr. Nelson has been a practicing hospitalist since 1988. He is co-founder and past president of SHM, and principal in Nelson Flores Hospital Medicine Consultants. He is co-director for SHM’s “Best Practices in Managing a Hospital Medicine Program” course. Write to him at [email protected].

Issue
The Hospitalist - 2013(09)
Publications
Sections

Sorting out whether a hospitalist’s bonus and other compensation elements are in line with survey data often leads to confusion. The 2013 MGMA Physician Compensation and Production Survey report, based on 2012 data, shows median compensation of $240,352 for internal-medicine hospitalists (I’ll round it to $240,000 for the rest of this piece). So is your compensation in line with survey medians if your base pay is $230,000 and you have a performance bonus of up to $20,000?

The problem is that you can’t know in advance how much of the $20,000 performance bonus you will earn. And isn’t a bonus supposed to be on top of typical compensation? To be in line with the survey, shouldn’t your base pay equal the $240,000 median, with any available bonus dollars on top of that? (Base pay means all forms of compensation other than a performance bonus; it could be productivity-based compensation, pay connected to numbers of shifts or hours worked, or a fixed annual salary, etc.)

The short answer is no, and to demonstrate why, I’ll first review some facts about the survey itself, then apply that knowledge to the hospitalist marketplace.

I want to emphasize that in this article, I’m not taking a position on the right amount of workload, compensation, or bonus for any hospitalist practice. And I’m using survey medians just to simplify the discussion, not because they’re optimal for any particular practice.

Survey Data

The most important thing to know about the survey data is that the $240,000 figure takes into account all forms of pay, including extra shift pay and any bonuses that might have been paid to each provider in the data set. Such benefits as health insurance and retirement-plan contribution are not included in this figure.

There are several ways a hospitalist might have earned compensation that matches the survey median. He or she might have a fixed annual salary equal to the median with no bonus available or had a meaningful bonus (e.g. $10,000 to $20,000) available and failed to earn any of it. Or the base might have come to $230,000, and he or she earned half of the available $20,000 performance bonus. Many other permutations of bonus and other salary elements could occur to arrive at the same $240,000 figure.

The important thing to remember is that whatever bonus dollars were paid, they are included in the salary figure from the survey—not added on top of that figure. So if all bonus dollars earned were subtracted from the survey, the total “nonbonus” compensation would be lower than $240,000.

How much lower?

If you follow the reasoning above, then you probably agree that if your goal is to match mean compensation from the MGMA survey, then you would set nonbonus compensation 7% below median—as long as you’re likely to get the same portion of a bonus as the median practice.

Typical Hospitalist Bonus Amounts

The MGMA survey doesn’t report the portion of compensation tied to a bonus, but SHM’s does. SHM’s 2012 State of Hospital Medicine Report, based on 2011 data (www.hospitalmedicine.org/survey), is based on the most recent data available, and it showed (on page 60) that an average of 7% of pay was tied to performance for nonacademic hospitalist groups serving adults only. This included any payments for good individual or group performance on quality, efficiency, service, satisfaction, and/or other nonproduction measures. In conversation, this often is referred to as a “bonus” rather than “performance compensation.”

One way to estimate the nonbonus compensation would be to reduce the total pay by 7%, which comes to $223,200. Keep in mind that there are all kinds of mathematical and methodological problems in manipulating the reported survey numbers from two separate surveys to derive additional benchmarks. But this seems like a reasonable guess.

 

 

An increasing portion of hospitalist groups have some pay tied to performance, and the portion of total pay tied to performance seems to be going up at least a little. It was 5% of pay in 2010 and 4% in 2011, compared with 7% in the 2012 survey.

Keep in mind two things. First, this 7% reflects the performance or bonus dollars actually paid out, not the total amount available. In other words, even if the median total bonus dollars available were 20% of compensation, hospitalists earned less than that. Some hospitalists earned all dollars available, and some earned only a portion of what was available. And second, some hospitalists fail to earn any bonus or don’t have one available at all. So the survey would show for them zero compensation tied to bonus.

Making Sense of the Numbers

If you follow the reasoning above, then you probably agree that if your goal is to match mean compensation from the MGMA survey (I’m not suggesting that is the best goal, merely using it for simplicity), then you would set nonbonus compensation 7% below median—as long as you’re likely to get the same portion of a bonus as the median practice.

In some practices, performance thresholds are set at a level that is very easy to achieve, meaning the hospitalists are almost guaranteed to get all of the bonus compensation available. To be consistent with survey medians, it would be appropriate for them to set nonbonus compensation by subtracting all bonus dollars from the survey median. For example, if a $20,000 bonus is available and all of it is likely to be earned by the hospitalists, then total nonbonus compensation would be $220,000.

However, what if the bonus requires significant improvements in performance by the doctors (which seems most appropriate to me; why have a bonus otherwise?) and it is likely they will earn only 25% of all bonus dollars available? If the total available bonus is $20,000, then something like 25%, or $5,000, should be subtracted from the median to yield a total nonbonus compensation of $235,000.

Simple Thinking

I think it makes most sense to set total nonbonus compensation below the targeted total compensation. Failure to achieve any performance thresholds means no bonus and compensation will be below target that year. Meeting some thresholds (some improvement in performance) should result in matching the target compensation, and truly terrific performance that meets or exceeds all thresholds should result in the doctor being paid above the target.


Dr. Nelson has been a practicing hospitalist since 1988. He is co-founder and past president of SHM, and principal in Nelson Flores Hospital Medicine Consultants. He is co-director for SHM’s “Best Practices in Managing a Hospital Medicine Program” course. Write to him at [email protected].

Sorting out whether a hospitalist’s bonus and other compensation elements are in line with survey data often leads to confusion. The 2013 MGMA Physician Compensation and Production Survey report, based on 2012 data, shows median compensation of $240,352 for internal-medicine hospitalists (I’ll round it to $240,000 for the rest of this piece). So is your compensation in line with survey medians if your base pay is $230,000 and you have a performance bonus of up to $20,000?

The problem is that you can’t know in advance how much of the $20,000 performance bonus you will earn. And isn’t a bonus supposed to be on top of typical compensation? To be in line with the survey, shouldn’t your base pay equal the $240,000 median, with any available bonus dollars on top of that? (Base pay means all forms of compensation other than a performance bonus; it could be productivity-based compensation, pay connected to numbers of shifts or hours worked, or a fixed annual salary, etc.)

The short answer is no, and to demonstrate why, I’ll first review some facts about the survey itself, then apply that knowledge to the hospitalist marketplace.

I want to emphasize that in this article, I’m not taking a position on the right amount of workload, compensation, or bonus for any hospitalist practice. And I’m using survey medians just to simplify the discussion, not because they’re optimal for any particular practice.

Survey Data

The most important thing to know about the survey data is that the $240,000 figure takes into account all forms of pay, including extra shift pay and any bonuses that might have been paid to each provider in the data set. Such benefits as health insurance and retirement-plan contribution are not included in this figure.

There are several ways a hospitalist might have earned compensation that matches the survey median. He or she might have a fixed annual salary equal to the median with no bonus available or had a meaningful bonus (e.g. $10,000 to $20,000) available and failed to earn any of it. Or the base might have come to $230,000, and he or she earned half of the available $20,000 performance bonus. Many other permutations of bonus and other salary elements could occur to arrive at the same $240,000 figure.

The important thing to remember is that whatever bonus dollars were paid, they are included in the salary figure from the survey—not added on top of that figure. So if all bonus dollars earned were subtracted from the survey, the total “nonbonus” compensation would be lower than $240,000.

How much lower?

If you follow the reasoning above, then you probably agree that if your goal is to match mean compensation from the MGMA survey, then you would set nonbonus compensation 7% below median—as long as you’re likely to get the same portion of a bonus as the median practice.

Typical Hospitalist Bonus Amounts

The MGMA survey doesn’t report the portion of compensation tied to a bonus, but SHM’s does. SHM’s 2012 State of Hospital Medicine Report, based on 2011 data (www.hospitalmedicine.org/survey), is based on the most recent data available, and it showed (on page 60) that an average of 7% of pay was tied to performance for nonacademic hospitalist groups serving adults only. This included any payments for good individual or group performance on quality, efficiency, service, satisfaction, and/or other nonproduction measures. In conversation, this often is referred to as a “bonus” rather than “performance compensation.”

One way to estimate the nonbonus compensation would be to reduce the total pay by 7%, which comes to $223,200. Keep in mind that there are all kinds of mathematical and methodological problems in manipulating the reported survey numbers from two separate surveys to derive additional benchmarks. But this seems like a reasonable guess.

 

 

An increasing portion of hospitalist groups have some pay tied to performance, and the portion of total pay tied to performance seems to be going up at least a little. It was 5% of pay in 2010 and 4% in 2011, compared with 7% in the 2012 survey.

Keep in mind two things. First, this 7% reflects the performance or bonus dollars actually paid out, not the total amount available. In other words, even if the median total bonus dollars available were 20% of compensation, hospitalists earned less than that. Some hospitalists earned all dollars available, and some earned only a portion of what was available. And second, some hospitalists fail to earn any bonus or don’t have one available at all. So the survey would show for them zero compensation tied to bonus.

Making Sense of the Numbers

If you follow the reasoning above, then you probably agree that if your goal is to match mean compensation from the MGMA survey (I’m not suggesting that is the best goal, merely using it for simplicity), then you would set nonbonus compensation 7% below median—as long as you’re likely to get the same portion of a bonus as the median practice.

In some practices, performance thresholds are set at a level that is very easy to achieve, meaning the hospitalists are almost guaranteed to get all of the bonus compensation available. To be consistent with survey medians, it would be appropriate for them to set nonbonus compensation by subtracting all bonus dollars from the survey median. For example, if a $20,000 bonus is available and all of it is likely to be earned by the hospitalists, then total nonbonus compensation would be $220,000.

However, what if the bonus requires significant improvements in performance by the doctors (which seems most appropriate to me; why have a bonus otherwise?) and it is likely they will earn only 25% of all bonus dollars available? If the total available bonus is $20,000, then something like 25%, or $5,000, should be subtracted from the median to yield a total nonbonus compensation of $235,000.

Simple Thinking

I think it makes most sense to set total nonbonus compensation below the targeted total compensation. Failure to achieve any performance thresholds means no bonus and compensation will be below target that year. Meeting some thresholds (some improvement in performance) should result in matching the target compensation, and truly terrific performance that meets or exceeds all thresholds should result in the doctor being paid above the target.


Dr. Nelson has been a practicing hospitalist since 1988. He is co-founder and past president of SHM, and principal in Nelson Flores Hospital Medicine Consultants. He is co-director for SHM’s “Best Practices in Managing a Hospital Medicine Program” course. Write to him at [email protected].

Issue
The Hospitalist - 2013(09)
Issue
The Hospitalist - 2013(09)
Publications
Publications
Article Type
Display Headline
MGMA Physician Compensation Survey Raises Questions About Performance Pay
Display Headline
MGMA Physician Compensation Survey Raises Questions About Performance Pay
Sections
Disallow All Ads
Content Gating
No Gating (article Unlocked/Free)

Patient Satisfaction Surveys Not Accurate Measure of Hospitalists’ Performance

Article Type
Changed
Wed, 03/27/2019 - 12:17
Display Headline
Patient Satisfaction Surveys Not Accurate Measure of Hospitalists’ Performance

The results of [hospitalist-specific patient satisfaction] surveys may form the basis of legitimate, targeted feedback to hospitalists, who may then adjust their approach to patient interactions.

Feeling frustrated with your group’s patient-satisfaction performance? Wondering why your chief (fill in the blank) officer glazes over when you try to explain why your hospitalist group’s Hospital Consumer Assessment of Healthcare Providers and System (HCAHPS) scores for doctor communication are in a percentile rivaling the numeric age of your children?

It is likely that the C-suite administrator overseeing your hospitalist group has a portion of their pay based on HCAHPS or other patient-satisfaction (also called patient experience) scores. And for good reason: The Centers for Medicare & Medicaid Services (CMS) Hospital Value-Based Purchasing (HVBP) program that started Oct. 1, 2012, has placed your hospital’s Medicare reimbursement at risk based on its HCAHPS scores.

HVBP and Patient Satisfaction

Patient satisfaction will remain an important part of HVBP in the coming years. Table 1 (below) shows the domains that will be included in fiscal years 2014 (which starts Oct. 1, 2013), 2015, and 2016. Table 2 (below) depicts the percent weighting the patient-satisfaction domain will receive through 2016. You may recall that HVBP is a program in which all hospitals place 1% to 2% (2013 through 2017, starting at 1% and increasing each year by 0.25% so that by 2017%, it is 2%) of their CMS inpatient payments in a withhold pool and, based on performance, can make back some, all, or an amount in excess of the amount placed in the withhold pool.

click for large version
Table 1. Patient experience measures: hospital value-based purchasing
Source: Federal Register Vol. 78, No. 91; May 10, 2013; Proposed Rules, pp. 27609-27622.

click for large version
Table 2. Hospital value-based purchasing weighting
Source: Federal Register Vol.78, No.91; May 10, 2013; Proposed Rules, pp. 27609-27622.

End In Itself

A colleague of mine recently asked, “Is an increase in patient satisfaction associated with higher quality of care and better patient safety?” The point here: It doesn’t matter. Patient satisfaction is an end in itself, and we should strive to maximize it, or at least put ourselves in the place of the patient and design care accordingly.

For Hospitalists: A Starting Point

There is a conundrum for hospitalists vis-à-vis patient satisfaction. Follow this chain of logic: The hospitals at which we work are incented to perform well on the HCAHPS domains. Hospitals pay a lot for hospitalists. Hospitalists can impact many of the HCAHPS domains. So shouldn’t hospitalists be judged according to HCAHPS scores?

Yes and no.

HCAHPS as a survey is intended to measure a patient’s overall experience of receiving care in the hospital. For example, from the “Doctor Communication” domain, we have questions like “how often did doctors treat you with courtesy and respect?” And “how often did doctors explain things in a way you could understand?”

These questions, like all in HCAHPS, are not designed to get at individual doctor performance, or even performance of a group of doctors, such as hospitalists. Instead, they are designed to measure a patient’s overall experience with the hospitalization, and “Doctor Communication” questions are designed to assess satisfaction with “doctors” collectively.

The Need for Hospitalist-Specific Satisfaction Surveys

So while HCAHPS is not designed to measure hospitalist performance with regard to patient satisfaction, it is a reasonable interim step for hospitals to judge hospitalists according to HCAHPS. However, this should be a bridge to a strategy that adopts hospitalist-specific patient-satisfaction questionnaires in the future and not an end in itself.

 

 

Why? Perhaps the biggest reason is that HCAHPS scores are neither specific nor timely enough to form the basis of improvement efforts for hospitalists. If a hospitalist receives a low score on the “Doctor Communication” domain, the scores are likely to be three to nine months old. How can we legitimately assign (and then modify) behaviors based on those scores?

Further, because the survey is not built to measure patient satisfaction specifically with hospitalists, the results are unlikely to engender meaningful and sustained behavior change. Hospitalists I talk to are generally bewildered and confused by HCAHPS scores attributed to them or their groups. Even if they understand the scores, I almost never see true quality improvement (plan-do-study-act) based on specific HCAHPS results. Instead, I see hospitalists trying to adhere to “best practices,” with no adjustments made along the way based on performance.

Nearly all the prominent patient satisfaction vendors have developed a survey instrument specifically designed for hospitalists. Each has an approach to appropriately attribute performance to the hospitalist in question, and each has a battery of questions that is designed to capture patient satisfaction with the hospitalist. Although use of these surveys involves an added financial commitment, I submit that because hospitalists have an unparalleled proximity to hospitalized patients, such an investment is worthy of consideration and has an accompanying business case, thanks to HVBP. The results of these surveys may form the basis of legitimate, targeted feedback to hospitalists, who may then adjust their approach to patient interactions. Such performance improvement should result in improved HCAHPS scores.

In sum, hospitalists should pay close attention to patient satisfaction and embrace HCAHPS. However, we should be looking beyond HCAHPS to survey instruments that fairly and accurately measure our performance. Such surveys will be more widely accepted by the hospitalists they are measuring, and will allow hospitalists to perform meaningful quality improvement based on the results. Although hospitalist-specific surveys will require an investment, the increased patient satisfaction that results should be the basis of a favorable return on that investment.


Dr. Whitcomb is medical director of healthcare quality at Baystate Medical Center in Springfield, Mass. He is co-founder and past president of SHM. Email him at [email protected].

Issue
The Hospitalist - 2013(09)
Publications
Topics
Sections

The results of [hospitalist-specific patient satisfaction] surveys may form the basis of legitimate, targeted feedback to hospitalists, who may then adjust their approach to patient interactions.

Feeling frustrated with your group’s patient-satisfaction performance? Wondering why your chief (fill in the blank) officer glazes over when you try to explain why your hospitalist group’s Hospital Consumer Assessment of Healthcare Providers and System (HCAHPS) scores for doctor communication are in a percentile rivaling the numeric age of your children?

It is likely that the C-suite administrator overseeing your hospitalist group has a portion of their pay based on HCAHPS or other patient-satisfaction (also called patient experience) scores. And for good reason: The Centers for Medicare & Medicaid Services (CMS) Hospital Value-Based Purchasing (HVBP) program that started Oct. 1, 2012, has placed your hospital’s Medicare reimbursement at risk based on its HCAHPS scores.

HVBP and Patient Satisfaction

Patient satisfaction will remain an important part of HVBP in the coming years. Table 1 (below) shows the domains that will be included in fiscal years 2014 (which starts Oct. 1, 2013), 2015, and 2016. Table 2 (below) depicts the percent weighting the patient-satisfaction domain will receive through 2016. You may recall that HVBP is a program in which all hospitals place 1% to 2% (2013 through 2017, starting at 1% and increasing each year by 0.25% so that by 2017%, it is 2%) of their CMS inpatient payments in a withhold pool and, based on performance, can make back some, all, or an amount in excess of the amount placed in the withhold pool.

click for large version
Table 1. Patient experience measures: hospital value-based purchasing
Source: Federal Register Vol. 78, No. 91; May 10, 2013; Proposed Rules, pp. 27609-27622.

click for large version
Table 2. Hospital value-based purchasing weighting
Source: Federal Register Vol.78, No.91; May 10, 2013; Proposed Rules, pp. 27609-27622.

End In Itself

A colleague of mine recently asked, “Is an increase in patient satisfaction associated with higher quality of care and better patient safety?” The point here: It doesn’t matter. Patient satisfaction is an end in itself, and we should strive to maximize it, or at least put ourselves in the place of the patient and design care accordingly.

For Hospitalists: A Starting Point

There is a conundrum for hospitalists vis-à-vis patient satisfaction. Follow this chain of logic: The hospitals at which we work are incented to perform well on the HCAHPS domains. Hospitals pay a lot for hospitalists. Hospitalists can impact many of the HCAHPS domains. So shouldn’t hospitalists be judged according to HCAHPS scores?

Yes and no.

HCAHPS as a survey is intended to measure a patient’s overall experience of receiving care in the hospital. For example, from the “Doctor Communication” domain, we have questions like “how often did doctors treat you with courtesy and respect?” And “how often did doctors explain things in a way you could understand?”

These questions, like all in HCAHPS, are not designed to get at individual doctor performance, or even performance of a group of doctors, such as hospitalists. Instead, they are designed to measure a patient’s overall experience with the hospitalization, and “Doctor Communication” questions are designed to assess satisfaction with “doctors” collectively.

The Need for Hospitalist-Specific Satisfaction Surveys

So while HCAHPS is not designed to measure hospitalist performance with regard to patient satisfaction, it is a reasonable interim step for hospitals to judge hospitalists according to HCAHPS. However, this should be a bridge to a strategy that adopts hospitalist-specific patient-satisfaction questionnaires in the future and not an end in itself.

 

 

Why? Perhaps the biggest reason is that HCAHPS scores are neither specific nor timely enough to form the basis of improvement efforts for hospitalists. If a hospitalist receives a low score on the “Doctor Communication” domain, the scores are likely to be three to nine months old. How can we legitimately assign (and then modify) behaviors based on those scores?

Further, because the survey is not built to measure patient satisfaction specifically with hospitalists, the results are unlikely to engender meaningful and sustained behavior change. Hospitalists I talk to are generally bewildered and confused by HCAHPS scores attributed to them or their groups. Even if they understand the scores, I almost never see true quality improvement (plan-do-study-act) based on specific HCAHPS results. Instead, I see hospitalists trying to adhere to “best practices,” with no adjustments made along the way based on performance.

Nearly all the prominent patient satisfaction vendors have developed a survey instrument specifically designed for hospitalists. Each has an approach to appropriately attribute performance to the hospitalist in question, and each has a battery of questions that is designed to capture patient satisfaction with the hospitalist. Although use of these surveys involves an added financial commitment, I submit that because hospitalists have an unparalleled proximity to hospitalized patients, such an investment is worthy of consideration and has an accompanying business case, thanks to HVBP. The results of these surveys may form the basis of legitimate, targeted feedback to hospitalists, who may then adjust their approach to patient interactions. Such performance improvement should result in improved HCAHPS scores.

In sum, hospitalists should pay close attention to patient satisfaction and embrace HCAHPS. However, we should be looking beyond HCAHPS to survey instruments that fairly and accurately measure our performance. Such surveys will be more widely accepted by the hospitalists they are measuring, and will allow hospitalists to perform meaningful quality improvement based on the results. Although hospitalist-specific surveys will require an investment, the increased patient satisfaction that results should be the basis of a favorable return on that investment.


Dr. Whitcomb is medical director of healthcare quality at Baystate Medical Center in Springfield, Mass. He is co-founder and past president of SHM. Email him at [email protected].

The results of [hospitalist-specific patient satisfaction] surveys may form the basis of legitimate, targeted feedback to hospitalists, who may then adjust their approach to patient interactions.

Feeling frustrated with your group’s patient-satisfaction performance? Wondering why your chief (fill in the blank) officer glazes over when you try to explain why your hospitalist group’s Hospital Consumer Assessment of Healthcare Providers and System (HCAHPS) scores for doctor communication are in a percentile rivaling the numeric age of your children?

It is likely that the C-suite administrator overseeing your hospitalist group has a portion of their pay based on HCAHPS or other patient-satisfaction (also called patient experience) scores. And for good reason: The Centers for Medicare & Medicaid Services (CMS) Hospital Value-Based Purchasing (HVBP) program that started Oct. 1, 2012, has placed your hospital’s Medicare reimbursement at risk based on its HCAHPS scores.

HVBP and Patient Satisfaction

Patient satisfaction will remain an important part of HVBP in the coming years. Table 1 (below) shows the domains that will be included in fiscal years 2014 (which starts Oct. 1, 2013), 2015, and 2016. Table 2 (below) depicts the percent weighting the patient-satisfaction domain will receive through 2016. You may recall that HVBP is a program in which all hospitals place 1% to 2% (2013 through 2017, starting at 1% and increasing each year by 0.25% so that by 2017%, it is 2%) of their CMS inpatient payments in a withhold pool and, based on performance, can make back some, all, or an amount in excess of the amount placed in the withhold pool.

click for large version
Table 1. Patient experience measures: hospital value-based purchasing
Source: Federal Register Vol. 78, No. 91; May 10, 2013; Proposed Rules, pp. 27609-27622.

click for large version
Table 2. Hospital value-based purchasing weighting
Source: Federal Register Vol.78, No.91; May 10, 2013; Proposed Rules, pp. 27609-27622.

End In Itself

A colleague of mine recently asked, “Is an increase in patient satisfaction associated with higher quality of care and better patient safety?” The point here: It doesn’t matter. Patient satisfaction is an end in itself, and we should strive to maximize it, or at least put ourselves in the place of the patient and design care accordingly.

For Hospitalists: A Starting Point

There is a conundrum for hospitalists vis-à-vis patient satisfaction. Follow this chain of logic: The hospitals at which we work are incented to perform well on the HCAHPS domains. Hospitals pay a lot for hospitalists. Hospitalists can impact many of the HCAHPS domains. So shouldn’t hospitalists be judged according to HCAHPS scores?

Yes and no.

HCAHPS as a survey is intended to measure a patient’s overall experience of receiving care in the hospital. For example, from the “Doctor Communication” domain, we have questions like “how often did doctors treat you with courtesy and respect?” And “how often did doctors explain things in a way you could understand?”

These questions, like all in HCAHPS, are not designed to get at individual doctor performance, or even performance of a group of doctors, such as hospitalists. Instead, they are designed to measure a patient’s overall experience with the hospitalization, and “Doctor Communication” questions are designed to assess satisfaction with “doctors” collectively.

The Need for Hospitalist-Specific Satisfaction Surveys

So while HCAHPS is not designed to measure hospitalist performance with regard to patient satisfaction, it is a reasonable interim step for hospitals to judge hospitalists according to HCAHPS. However, this should be a bridge to a strategy that adopts hospitalist-specific patient-satisfaction questionnaires in the future and not an end in itself.

 

 

Why? Perhaps the biggest reason is that HCAHPS scores are neither specific nor timely enough to form the basis of improvement efforts for hospitalists. If a hospitalist receives a low score on the “Doctor Communication” domain, the scores are likely to be three to nine months old. How can we legitimately assign (and then modify) behaviors based on those scores?

Further, because the survey is not built to measure patient satisfaction specifically with hospitalists, the results are unlikely to engender meaningful and sustained behavior change. Hospitalists I talk to are generally bewildered and confused by HCAHPS scores attributed to them or their groups. Even if they understand the scores, I almost never see true quality improvement (plan-do-study-act) based on specific HCAHPS results. Instead, I see hospitalists trying to adhere to “best practices,” with no adjustments made along the way based on performance.

Nearly all the prominent patient satisfaction vendors have developed a survey instrument specifically designed for hospitalists. Each has an approach to appropriately attribute performance to the hospitalist in question, and each has a battery of questions that is designed to capture patient satisfaction with the hospitalist. Although use of these surveys involves an added financial commitment, I submit that because hospitalists have an unparalleled proximity to hospitalized patients, such an investment is worthy of consideration and has an accompanying business case, thanks to HVBP. The results of these surveys may form the basis of legitimate, targeted feedback to hospitalists, who may then adjust their approach to patient interactions. Such performance improvement should result in improved HCAHPS scores.

In sum, hospitalists should pay close attention to patient satisfaction and embrace HCAHPS. However, we should be looking beyond HCAHPS to survey instruments that fairly and accurately measure our performance. Such surveys will be more widely accepted by the hospitalists they are measuring, and will allow hospitalists to perform meaningful quality improvement based on the results. Although hospitalist-specific surveys will require an investment, the increased patient satisfaction that results should be the basis of a favorable return on that investment.


Dr. Whitcomb is medical director of healthcare quality at Baystate Medical Center in Springfield, Mass. He is co-founder and past president of SHM. Email him at [email protected].

Issue
The Hospitalist - 2013(09)
Issue
The Hospitalist - 2013(09)
Publications
Publications
Topics
Article Type
Display Headline
Patient Satisfaction Surveys Not Accurate Measure of Hospitalists’ Performance
Display Headline
Patient Satisfaction Surveys Not Accurate Measure of Hospitalists’ Performance
Sections
Disallow All Ads
Content Gating
No Gating (article Unlocked/Free)

Which abnormal ovarian findings can be followed by serial TVUS?

Article Type
Changed
Tue, 08/28/2018 - 11:02
Display Headline
Which abnormal ovarian findings can be followed by serial TVUS?

Ovarian cancer causes more deaths than any other cancer affecting the female reproductive system.1 One reason it’s so deadly: It usually isn’t detected until it has reached an advanced stage. No clear-cut symptoms point definitively to ovarian malignancy, and no feasible screening strategy has been found to increase detection at an early stage.

Among the strategies that have been utilized to detect ovarian cancer are bimanual examination of the adnexae (primarily in postmenopausal women), measurement of cancer antigen (CA) 125, and transvaginal ultrasonography (TVUS) of the ovaries. The last two strategies sometimes are combined in high-risk women.

TVUS can highlight ovarian abnormalities and provide information about their structure. The question then becomes which abnormalities are likely to resolve without treatment, and which should be scrutinized more closely. In this study, Pavlik and colleagues reviewed TVUS findings from 39,337 women enrolled in the University of Kentucky Ovarian Cancer Screening Program, which involved 221,576 baseline and interval TVUS scans.

Details of the study
Women in this study were screened with annual TVUS scans between 1987 and 2002. The population included:

  • asymptomatic women aged 50 or older
  • asymptomatic women over age 25 who had a first- or second-degree relative with documented ovarian cancer.

The initial TVUS scan was normal in almost 90% of women, and only about 10% subsequently experienced an abnormal scan. About half (46.7%) of the ovarian abnormalities identified via TVUS were found on the very first scan. Of these, 63.2% resolved during follow-up with no treatment.

Approximately 80% of women had no abnormal TVUS findings at any time during the observation period. This is notable because participants had a high risk for ovarian cancer by virtue of advanced age or family history.

TVUS abnormalities had a higher prevalence in premenopausal women (35%) than in postmenopausal women (17%; P<.001). The incidence of ovarian cysts also was significantly higher among premenopausal women (15.3% vs 8.2%; P<.001). These differences are to be expected, owing to the functional nature of premenopausal ovaries in regard to folliculogenesis, ovulation, and endometriosis.

Positive predictive values ranged from 15.3% to 24.7%
Over the 25 years covered by this study, our understanding of the malignant potential of various ovarian masses has evolved considerably. We have long known that unilocular cysts are extremely unlikely to be malignant, but now we are aware that even septated cysts are unlikely to represent cancer.

As for the success of this ovarian cancer-screening program, which identified 85 true malignancies and 472 nonmalignancies in surgical specimens, it had an overall positive predictive value of 15.3%. After January 1, 2008, however, when serial observation expanded to include septated cysts (because published data confirmed these masses to have low malignant potential), positive predictive value improved to 24.7%.

Pavlik and colleagues also discussed findings from the Prostate, Lung, Colorectal, and Ovarian (PLCO) Cancer Screening Trial, which relied on a single TVUS abnormality to trigger a recommendation for surgery, with a positive predictive value of only 5.1%.2

Most cancers were diagnosed at an early stage
Of the invasive epithelial cancers identified in this study, the stage distribution at diagnosis was:

  • Stage 1: 45%
  • Stage 2: 23%
  • Stage 3: 32%
  • Stage 4: None.

This finding is notable, given statistics from the “real world,” where about 80% of ovarian cancers are diagnosed at Stage 3 or Stage 4.

Among benign findings that were managed surgically, 47% were serous cystadenomas, 13% were hemorrhagic cysts, 9% were fibromas, thecomas, or Brenner tumors, and the rest were fairly equally divided between hydrosalpinx or paratubal cysts; endometriomas; and mucinous cystadenomas, leiomyomas, and cystic teratomas.

What this evidence means for practice

In general, unilocular or septate cysts can be followed every 6 months by TVUS. Although more complex tumors may resolve spontaneously, they should be followed with serial TVUS, with caution, at intervals of 6 weeks to 3 months. The findings of each scan should determine the subsequent course of action, which could involve further monitoring or surgical extirpation.

Regrettably, this study did not utilize color flow Doppler imaging. Because malignant tumors are rich in neovascularity, and the vessels laid down by such tumors often lack a normal media layer, they often exhibit very low resistance to flow. Although neovascularity is not a perfect diagnostic indicator of malignancy, the presence of abundant blood flow and low resistance can raise the index of suspicion. In my opinion, color flow Doppler should be incorporated into ultrasonographic evaluation of potential ovarian malignancies.

—Steven R. Goldstein, MD

Tell us what you think, at [email protected]. Please include your name and city and state.

References

1. American Cancer Society. Cancer Facts and Figures, 2013. http://www.cancer.org/acs/groups/content/@e p i d e m i o l o g y s u r v e i l a n c e / d o c u m e n t s / d o c u m e n t/acspc-036845.pdf. Accessed August 20, 2013.

2. Buys SS, Partridge E, Black A, et al. Effect of screening on ovarian cancer mortality—the Prostate, Lung, Colorectal and Ovarian (PLCO) Cancer Screening Randomized Controlled Trial. JAMA. 2011;305(22):2295–2303.

Author and Disclosure Information

Steven R. Goldstein, MD Professor of Obstetrics and Gynecology, New York University School of Medicine. Dr. Goldstein is Director of Gynecologic Ultrasound and Co-Director of Bone Densitometry at New York University Medical Center in New York City. He serves on the OBG Management Board of Editors.

The author reports no financial relationships relevant to this article.

Issue
OBG Management - 25(9)
Publications
Topics
Page Number
21, 34
Legacy Keywords
Which abnormal ovarian findings can be followed by serial TVUS?, Examining the Evidence, serial transvaginal ultrasound, serial TVUS, TVUS, unilocular cysts, septate cysts, abnormal ovarian findings, ovarian malignancy, color Doppler flow, Steven Goldstein MD
Sections
Author and Disclosure Information

Steven R. Goldstein, MD Professor of Obstetrics and Gynecology, New York University School of Medicine. Dr. Goldstein is Director of Gynecologic Ultrasound and Co-Director of Bone Densitometry at New York University Medical Center in New York City. He serves on the OBG Management Board of Editors.

The author reports no financial relationships relevant to this article.

Author and Disclosure Information

Steven R. Goldstein, MD Professor of Obstetrics and Gynecology, New York University School of Medicine. Dr. Goldstein is Director of Gynecologic Ultrasound and Co-Director of Bone Densitometry at New York University Medical Center in New York City. He serves on the OBG Management Board of Editors.

The author reports no financial relationships relevant to this article.

Related Articles

Ovarian cancer causes more deaths than any other cancer affecting the female reproductive system.1 One reason it’s so deadly: It usually isn’t detected until it has reached an advanced stage. No clear-cut symptoms point definitively to ovarian malignancy, and no feasible screening strategy has been found to increase detection at an early stage.

Among the strategies that have been utilized to detect ovarian cancer are bimanual examination of the adnexae (primarily in postmenopausal women), measurement of cancer antigen (CA) 125, and transvaginal ultrasonography (TVUS) of the ovaries. The last two strategies sometimes are combined in high-risk women.

TVUS can highlight ovarian abnormalities and provide information about their structure. The question then becomes which abnormalities are likely to resolve without treatment, and which should be scrutinized more closely. In this study, Pavlik and colleagues reviewed TVUS findings from 39,337 women enrolled in the University of Kentucky Ovarian Cancer Screening Program, which involved 221,576 baseline and interval TVUS scans.

Details of the study
Women in this study were screened with annual TVUS scans between 1987 and 2002. The population included:

  • asymptomatic women aged 50 or older
  • asymptomatic women over age 25 who had a first- or second-degree relative with documented ovarian cancer.

The initial TVUS scan was normal in almost 90% of women, and only about 10% subsequently experienced an abnormal scan. About half (46.7%) of the ovarian abnormalities identified via TVUS were found on the very first scan. Of these, 63.2% resolved during follow-up with no treatment.

Approximately 80% of women had no abnormal TVUS findings at any time during the observation period. This is notable because participants had a high risk for ovarian cancer by virtue of advanced age or family history.

TVUS abnormalities had a higher prevalence in premenopausal women (35%) than in postmenopausal women (17%; P<.001). The incidence of ovarian cysts also was significantly higher among premenopausal women (15.3% vs 8.2%; P<.001). These differences are to be expected, owing to the functional nature of premenopausal ovaries in regard to folliculogenesis, ovulation, and endometriosis.

Positive predictive values ranged from 15.3% to 24.7%
Over the 25 years covered by this study, our understanding of the malignant potential of various ovarian masses has evolved considerably. We have long known that unilocular cysts are extremely unlikely to be malignant, but now we are aware that even septated cysts are unlikely to represent cancer.

As for the success of this ovarian cancer-screening program, which identified 85 true malignancies and 472 nonmalignancies in surgical specimens, it had an overall positive predictive value of 15.3%. After January 1, 2008, however, when serial observation expanded to include septated cysts (because published data confirmed these masses to have low malignant potential), positive predictive value improved to 24.7%.

Pavlik and colleagues also discussed findings from the Prostate, Lung, Colorectal, and Ovarian (PLCO) Cancer Screening Trial, which relied on a single TVUS abnormality to trigger a recommendation for surgery, with a positive predictive value of only 5.1%.2

Most cancers were diagnosed at an early stage
Of the invasive epithelial cancers identified in this study, the stage distribution at diagnosis was:

  • Stage 1: 45%
  • Stage 2: 23%
  • Stage 3: 32%
  • Stage 4: None.

This finding is notable, given statistics from the “real world,” where about 80% of ovarian cancers are diagnosed at Stage 3 or Stage 4.

Among benign findings that were managed surgically, 47% were serous cystadenomas, 13% were hemorrhagic cysts, 9% were fibromas, thecomas, or Brenner tumors, and the rest were fairly equally divided between hydrosalpinx or paratubal cysts; endometriomas; and mucinous cystadenomas, leiomyomas, and cystic teratomas.

What this evidence means for practice

In general, unilocular or septate cysts can be followed every 6 months by TVUS. Although more complex tumors may resolve spontaneously, they should be followed with serial TVUS, with caution, at intervals of 6 weeks to 3 months. The findings of each scan should determine the subsequent course of action, which could involve further monitoring or surgical extirpation.

Regrettably, this study did not utilize color flow Doppler imaging. Because malignant tumors are rich in neovascularity, and the vessels laid down by such tumors often lack a normal media layer, they often exhibit very low resistance to flow. Although neovascularity is not a perfect diagnostic indicator of malignancy, the presence of abundant blood flow and low resistance can raise the index of suspicion. In my opinion, color flow Doppler should be incorporated into ultrasonographic evaluation of potential ovarian malignancies.

—Steven R. Goldstein, MD

Tell us what you think, at [email protected]. Please include your name and city and state.

Ovarian cancer causes more deaths than any other cancer affecting the female reproductive system.1 One reason it’s so deadly: It usually isn’t detected until it has reached an advanced stage. No clear-cut symptoms point definitively to ovarian malignancy, and no feasible screening strategy has been found to increase detection at an early stage.

Among the strategies that have been utilized to detect ovarian cancer are bimanual examination of the adnexae (primarily in postmenopausal women), measurement of cancer antigen (CA) 125, and transvaginal ultrasonography (TVUS) of the ovaries. The last two strategies sometimes are combined in high-risk women.

TVUS can highlight ovarian abnormalities and provide information about their structure. The question then becomes which abnormalities are likely to resolve without treatment, and which should be scrutinized more closely. In this study, Pavlik and colleagues reviewed TVUS findings from 39,337 women enrolled in the University of Kentucky Ovarian Cancer Screening Program, which involved 221,576 baseline and interval TVUS scans.

Details of the study
Women in this study were screened with annual TVUS scans between 1987 and 2002. The population included:

  • asymptomatic women aged 50 or older
  • asymptomatic women over age 25 who had a first- or second-degree relative with documented ovarian cancer.

The initial TVUS scan was normal in almost 90% of women, and only about 10% subsequently experienced an abnormal scan. About half (46.7%) of the ovarian abnormalities identified via TVUS were found on the very first scan. Of these, 63.2% resolved during follow-up with no treatment.

Approximately 80% of women had no abnormal TVUS findings at any time during the observation period. This is notable because participants had a high risk for ovarian cancer by virtue of advanced age or family history.

TVUS abnormalities had a higher prevalence in premenopausal women (35%) than in postmenopausal women (17%; P<.001). The incidence of ovarian cysts also was significantly higher among premenopausal women (15.3% vs 8.2%; P<.001). These differences are to be expected, owing to the functional nature of premenopausal ovaries in regard to folliculogenesis, ovulation, and endometriosis.

Positive predictive values ranged from 15.3% to 24.7%
Over the 25 years covered by this study, our understanding of the malignant potential of various ovarian masses has evolved considerably. We have long known that unilocular cysts are extremely unlikely to be malignant, but now we are aware that even septated cysts are unlikely to represent cancer.

As for the success of this ovarian cancer-screening program, which identified 85 true malignancies and 472 nonmalignancies in surgical specimens, it had an overall positive predictive value of 15.3%. After January 1, 2008, however, when serial observation expanded to include septated cysts (because published data confirmed these masses to have low malignant potential), positive predictive value improved to 24.7%.

Pavlik and colleagues also discussed findings from the Prostate, Lung, Colorectal, and Ovarian (PLCO) Cancer Screening Trial, which relied on a single TVUS abnormality to trigger a recommendation for surgery, with a positive predictive value of only 5.1%.2

Most cancers were diagnosed at an early stage
Of the invasive epithelial cancers identified in this study, the stage distribution at diagnosis was:

  • Stage 1: 45%
  • Stage 2: 23%
  • Stage 3: 32%
  • Stage 4: None.

This finding is notable, given statistics from the “real world,” where about 80% of ovarian cancers are diagnosed at Stage 3 or Stage 4.

Among benign findings that were managed surgically, 47% were serous cystadenomas, 13% were hemorrhagic cysts, 9% were fibromas, thecomas, or Brenner tumors, and the rest were fairly equally divided between hydrosalpinx or paratubal cysts; endometriomas; and mucinous cystadenomas, leiomyomas, and cystic teratomas.

What this evidence means for practice

In general, unilocular or septate cysts can be followed every 6 months by TVUS. Although more complex tumors may resolve spontaneously, they should be followed with serial TVUS, with caution, at intervals of 6 weeks to 3 months. The findings of each scan should determine the subsequent course of action, which could involve further monitoring or surgical extirpation.

Regrettably, this study did not utilize color flow Doppler imaging. Because malignant tumors are rich in neovascularity, and the vessels laid down by such tumors often lack a normal media layer, they often exhibit very low resistance to flow. Although neovascularity is not a perfect diagnostic indicator of malignancy, the presence of abundant blood flow and low resistance can raise the index of suspicion. In my opinion, color flow Doppler should be incorporated into ultrasonographic evaluation of potential ovarian malignancies.

—Steven R. Goldstein, MD

Tell us what you think, at [email protected]. Please include your name and city and state.

References

1. American Cancer Society. Cancer Facts and Figures, 2013. http://www.cancer.org/acs/groups/content/@e p i d e m i o l o g y s u r v e i l a n c e / d o c u m e n t s / d o c u m e n t/acspc-036845.pdf. Accessed August 20, 2013.

2. Buys SS, Partridge E, Black A, et al. Effect of screening on ovarian cancer mortality—the Prostate, Lung, Colorectal and Ovarian (PLCO) Cancer Screening Randomized Controlled Trial. JAMA. 2011;305(22):2295–2303.

References

1. American Cancer Society. Cancer Facts and Figures, 2013. http://www.cancer.org/acs/groups/content/@e p i d e m i o l o g y s u r v e i l a n c e / d o c u m e n t s / d o c u m e n t/acspc-036845.pdf. Accessed August 20, 2013.

2. Buys SS, Partridge E, Black A, et al. Effect of screening on ovarian cancer mortality—the Prostate, Lung, Colorectal and Ovarian (PLCO) Cancer Screening Randomized Controlled Trial. JAMA. 2011;305(22):2295–2303.

Issue
OBG Management - 25(9)
Issue
OBG Management - 25(9)
Page Number
21, 34
Page Number
21, 34
Publications
Publications
Topics
Article Type
Display Headline
Which abnormal ovarian findings can be followed by serial TVUS?
Display Headline
Which abnormal ovarian findings can be followed by serial TVUS?
Legacy Keywords
Which abnormal ovarian findings can be followed by serial TVUS?, Examining the Evidence, serial transvaginal ultrasound, serial TVUS, TVUS, unilocular cysts, septate cysts, abnormal ovarian findings, ovarian malignancy, color Doppler flow, Steven Goldstein MD
Legacy Keywords
Which abnormal ovarian findings can be followed by serial TVUS?, Examining the Evidence, serial transvaginal ultrasound, serial TVUS, TVUS, unilocular cysts, septate cysts, abnormal ovarian findings, ovarian malignancy, color Doppler flow, Steven Goldstein MD
Sections
Article Source

PURLs Copyright

Inside the Article

Has the evidence tipped in favor of delayed cord clamping?

Article Type
Changed
Tue, 08/28/2018 - 11:02
Display Headline
Has the evidence tipped in favor of delayed cord clamping?

In December 2012, the American College of Obstetricians and Gynecologists
(ACOG) published a Committee Opinion on the timing of umbilical cord clamping after birth, but it found insufficient evidence to recommend early or delayed clamping.1

In a Cochrane review published earlier this year, McDonald and colleagues reviewed 15 trials and 3,911 mother-infant pairs, exploring the primary outcomes of severe maternal postpartum hemorrhage (≥1,000 mL), maternal death, and severe maternal morbidity and neonatal death associated with early versus delayed clamping. They also analyzed a number of secondary outcomes. None of the primary outcomes reached statistical significance.

In a statement from the World Health Organization (WHO) included in the Cochrane review, it was recommended that “the cord should not be clamped earlier than necessary”; the WHO graded this as a “weak recommendation”
based on “low-quality” evidence.

With such underwhelming evidence, I would guess that the average clinician does not feel very motivated to change his or her practice, if that practice involves early clamping.

One limitation of the Cochrane findings
In the studies included in the Cochrane review, there was marked heterogeneity in the definition of delayed cord clamping, which ranged
from 1 minute after delivery to the complete cessation of cord pulsation (~5 minutes). Some of the studies even used alternate times (2 minutes, 3 minutes, and so on).

Delayed clamping improved neonatal hemoglobin status
Among the secondary outcomes assessed in this review was an improvement in neonatal hemoglobin concentration and overall iron stores associated with delayed clamping—but this benefit came at the expense of a higher incidence of neonatal jaundice requiring phototherapy. As a result, the investigators
concluded that delayed cord clamping should be performed when there is ready
access to phototherapy.

Should we implement delayed clamping?
At this time, I am reluctant to recommend that we shift to delayed clamping. Here are my reasons:

  • Data are lacking as to whether increased hemoglobin levels and iron stores in newborns improve outcomes—or provide any benefit. No long-term developmental outcome data were included in the Cochrane review.
  • Although I am not a pediatrician, I am unaware of infant iron deficiency being a significant threat to public health in the developed world.
  • The greater need for phototherapy in the delayed-clamping group should not be viewed as inconsequential.
  • Iron supplementation is probably more readily available than phototherapy, especially in developing countries.
  • In the minority of cases in which delayed clamping might be beneficial (eg, prematurity), it is not always feasible, as these infants may already be compromised. Anxious neonatologists generally want the newborn handed over to them for resuscitation as quickly as possible, generally frowning upon a delay of 3 to 5 minutes for the blood to move from the placenta to the infant.

What this evidence means for practice
I recommend that obstetric care providers continue their current practice until more detailed data emerge on the risks and benefits of delayed clamping. If a patient asks about the issue, we should counsel her about the risks and benefits of early versus delayed clamping and comply with her choice when there are no contraindications.
—John T. Repke, MD

Tell us what you think, at [email protected]. Please include your name and city and state.

References

Reference

1. American College of Obstetricians and Gynecologists. Committee Opinion #543: Timing of umbilical cord clamping after birth. Obstet Gynecol. 2012:120(6):1522–1526.

Article PDF
Author and Disclosure Information

John T. Repke, MD

University Professor and Chairman, Department of Obstetrics and Gynecology, Penn State University College of Medicine, and Obstetrician-Gynecologist-in-Chief, Milton S. Hershey Medical Center, Hershey, Pennsylvania. Dr. Repke serves on the OBG Management Board of Editors.

The author reports no financial relationships relevant to this article.

Issue
OBG Management - 25(9)
Publications
Topics
Legacy Keywords
Examining the Evidence, John T. Repke MD, has the evidence tipped in favor of delayed cord clamping?, evidence, delayed, cord, clamping, delayed cord clamping, neonatal outcomes, umbilical cord clamping, delayed umbilical cord clamping, outcomes, maternal outcomes, John Repke
Sections
Author and Disclosure Information

John T. Repke, MD

University Professor and Chairman, Department of Obstetrics and Gynecology, Penn State University College of Medicine, and Obstetrician-Gynecologist-in-Chief, Milton S. Hershey Medical Center, Hershey, Pennsylvania. Dr. Repke serves on the OBG Management Board of Editors.

The author reports no financial relationships relevant to this article.

Author and Disclosure Information

John T. Repke, MD

University Professor and Chairman, Department of Obstetrics and Gynecology, Penn State University College of Medicine, and Obstetrician-Gynecologist-in-Chief, Milton S. Hershey Medical Center, Hershey, Pennsylvania. Dr. Repke serves on the OBG Management Board of Editors.

The author reports no financial relationships relevant to this article.

Article PDF
Article PDF
Related Articles

In December 2012, the American College of Obstetricians and Gynecologists
(ACOG) published a Committee Opinion on the timing of umbilical cord clamping after birth, but it found insufficient evidence to recommend early or delayed clamping.1

In a Cochrane review published earlier this year, McDonald and colleagues reviewed 15 trials and 3,911 mother-infant pairs, exploring the primary outcomes of severe maternal postpartum hemorrhage (≥1,000 mL), maternal death, and severe maternal morbidity and neonatal death associated with early versus delayed clamping. They also analyzed a number of secondary outcomes. None of the primary outcomes reached statistical significance.

In a statement from the World Health Organization (WHO) included in the Cochrane review, it was recommended that “the cord should not be clamped earlier than necessary”; the WHO graded this as a “weak recommendation”
based on “low-quality” evidence.

With such underwhelming evidence, I would guess that the average clinician does not feel very motivated to change his or her practice, if that practice involves early clamping.

One limitation of the Cochrane findings
In the studies included in the Cochrane review, there was marked heterogeneity in the definition of delayed cord clamping, which ranged
from 1 minute after delivery to the complete cessation of cord pulsation (~5 minutes). Some of the studies even used alternate times (2 minutes, 3 minutes, and so on).

Delayed clamping improved neonatal hemoglobin status
Among the secondary outcomes assessed in this review was an improvement in neonatal hemoglobin concentration and overall iron stores associated with delayed clamping—but this benefit came at the expense of a higher incidence of neonatal jaundice requiring phototherapy. As a result, the investigators
concluded that delayed cord clamping should be performed when there is ready
access to phototherapy.

Should we implement delayed clamping?
At this time, I am reluctant to recommend that we shift to delayed clamping. Here are my reasons:

  • Data are lacking as to whether increased hemoglobin levels and iron stores in newborns improve outcomes—or provide any benefit. No long-term developmental outcome data were included in the Cochrane review.
  • Although I am not a pediatrician, I am unaware of infant iron deficiency being a significant threat to public health in the developed world.
  • The greater need for phototherapy in the delayed-clamping group should not be viewed as inconsequential.
  • Iron supplementation is probably more readily available than phototherapy, especially in developing countries.
  • In the minority of cases in which delayed clamping might be beneficial (eg, prematurity), it is not always feasible, as these infants may already be compromised. Anxious neonatologists generally want the newborn handed over to them for resuscitation as quickly as possible, generally frowning upon a delay of 3 to 5 minutes for the blood to move from the placenta to the infant.

What this evidence means for practice
I recommend that obstetric care providers continue their current practice until more detailed data emerge on the risks and benefits of delayed clamping. If a patient asks about the issue, we should counsel her about the risks and benefits of early versus delayed clamping and comply with her choice when there are no contraindications.
—John T. Repke, MD

Tell us what you think, at [email protected]. Please include your name and city and state.

In December 2012, the American College of Obstetricians and Gynecologists
(ACOG) published a Committee Opinion on the timing of umbilical cord clamping after birth, but it found insufficient evidence to recommend early or delayed clamping.1

In a Cochrane review published earlier this year, McDonald and colleagues reviewed 15 trials and 3,911 mother-infant pairs, exploring the primary outcomes of severe maternal postpartum hemorrhage (≥1,000 mL), maternal death, and severe maternal morbidity and neonatal death associated with early versus delayed clamping. They also analyzed a number of secondary outcomes. None of the primary outcomes reached statistical significance.

In a statement from the World Health Organization (WHO) included in the Cochrane review, it was recommended that “the cord should not be clamped earlier than necessary”; the WHO graded this as a “weak recommendation”
based on “low-quality” evidence.

With such underwhelming evidence, I would guess that the average clinician does not feel very motivated to change his or her practice, if that practice involves early clamping.

One limitation of the Cochrane findings
In the studies included in the Cochrane review, there was marked heterogeneity in the definition of delayed cord clamping, which ranged
from 1 minute after delivery to the complete cessation of cord pulsation (~5 minutes). Some of the studies even used alternate times (2 minutes, 3 minutes, and so on).

Delayed clamping improved neonatal hemoglobin status
Among the secondary outcomes assessed in this review was an improvement in neonatal hemoglobin concentration and overall iron stores associated with delayed clamping—but this benefit came at the expense of a higher incidence of neonatal jaundice requiring phototherapy. As a result, the investigators
concluded that delayed cord clamping should be performed when there is ready
access to phototherapy.

Should we implement delayed clamping?
At this time, I am reluctant to recommend that we shift to delayed clamping. Here are my reasons:

  • Data are lacking as to whether increased hemoglobin levels and iron stores in newborns improve outcomes—or provide any benefit. No long-term developmental outcome data were included in the Cochrane review.
  • Although I am not a pediatrician, I am unaware of infant iron deficiency being a significant threat to public health in the developed world.
  • The greater need for phototherapy in the delayed-clamping group should not be viewed as inconsequential.
  • Iron supplementation is probably more readily available than phototherapy, especially in developing countries.
  • In the minority of cases in which delayed clamping might be beneficial (eg, prematurity), it is not always feasible, as these infants may already be compromised. Anxious neonatologists generally want the newborn handed over to them for resuscitation as quickly as possible, generally frowning upon a delay of 3 to 5 minutes for the blood to move from the placenta to the infant.

What this evidence means for practice
I recommend that obstetric care providers continue their current practice until more detailed data emerge on the risks and benefits of delayed clamping. If a patient asks about the issue, we should counsel her about the risks and benefits of early versus delayed clamping and comply with her choice when there are no contraindications.
—John T. Repke, MD

Tell us what you think, at [email protected]. Please include your name and city and state.

References

Reference

1. American College of Obstetricians and Gynecologists. Committee Opinion #543: Timing of umbilical cord clamping after birth. Obstet Gynecol. 2012:120(6):1522–1526.

References

Reference

1. American College of Obstetricians and Gynecologists. Committee Opinion #543: Timing of umbilical cord clamping after birth. Obstet Gynecol. 2012:120(6):1522–1526.

Issue
OBG Management - 25(9)
Issue
OBG Management - 25(9)
Publications
Publications
Topics
Article Type
Display Headline
Has the evidence tipped in favor of delayed cord clamping?
Display Headline
Has the evidence tipped in favor of delayed cord clamping?
Legacy Keywords
Examining the Evidence, John T. Repke MD, has the evidence tipped in favor of delayed cord clamping?, evidence, delayed, cord, clamping, delayed cord clamping, neonatal outcomes, umbilical cord clamping, delayed umbilical cord clamping, outcomes, maternal outcomes, John Repke
Legacy Keywords
Examining the Evidence, John T. Repke MD, has the evidence tipped in favor of delayed cord clamping?, evidence, delayed, cord, clamping, delayed cord clamping, neonatal outcomes, umbilical cord clamping, delayed umbilical cord clamping, outcomes, maternal outcomes, John Repke
Sections
Article Source

PURLs Copyright

Inside the Article
Article PDF Media

Bundled-Payment Program Basics

Article Type
Changed
Wed, 03/27/2019 - 12:18
Display Headline
Bundled-Payment Program Basics

With general agreement that health-care costs in the U.S. are unsustainable, the Centers for Medicare & Medicaid Services (CMS), through the Center for Medicare and Medicaid Innovation (CMMI), and the private sector are embarking on new approaches to cost containment. On the one hand, we have value-based purchasing (VBP), which rests on the existing fee-for-service system and aims for incremental change. On the other hand, we have accountable-care organizations (ACOs), which provide a global payment for a population of patients, and bundled-payment programs, which provide a single payment for an episode of care. These reimbursement models represent a fundamental change in how we pay for health care.

On a broad scale, ACOs may be further along in development than bundled-payment programs, even though pockets of bundling prototypes have existed for years. Examples include the Prometheus payment system, Geisinger’s ProvenCare, and CMS’ Acute Care Episode demonstration project, which bundled Part A (hospital) and Part B (doctors, others) payments for cardiac and orthopedic surgery procedures. Over the past two years, we have seen a dramatic uptick in bundling activity, including programs in a number of states (including Arkansas, California, and Massachusetts). Here at Baystate Health in Massachusetts, we kicked off a total-hip-replacement bundle with our subsidiary health plan in January 2011.

With most patients in surgical or medical bundles being discharged to home, we now recognize that PCPs will be essential to the success of a bundle.

Opportunities to contribute to bundled-payment programs

  • Work on teams to develop new care models for the program.
  • Optimize surgical patients preoperatively and comanage in the perioperative period to prevent complications.
  • Aid in ideal care transition from hospital to home or facility.
  • Provide direct post-acute-facility management to ensure ideal recovery and prevent readmissions.

Financial scenarios for hospitalists in bundled-payment programs

  • If hospitalists contribute to savings and are eligible to receive shared savings, such savings will represent a new revenue stream.
  • Hospitalists may be on the hook for care and costs over which they have little or no control (e.g. surgical or post-acute ambulatory care).
  • Hospitalists may be left out of bundled payments altogether and be paid solely fee for service.

Perhaps most notably, bundled payments are part of the Affordable Care Act. The Bundled Payments for Care Improvement initiative, launched earlier this year by CMMI, is enrolling traditional Medicare patients in bundled-payment programs across the country at more than 400 health systems.

How Bundled Payments Work

Bundled-payment programs provide a single payment to hospitals, doctors, post-acute providers, and other providers (for home care, lab, medical equipment, etc.) for a defined episode of care. Most bundles encompass at least an acute hospital episode and physician payments for the episode; many include some period after hospitalization, covering rehabilitation at a facility or at home and doctors’ visits during recovery. Bundling goes beyond Medicare’s diagnosis-related group (DRG) payments, which reimburse hospitals for all elements of an inpatient hospital stay for a given diagnosis but do not include services performed by nonhospital providers.

How do the finances work in a bundled-payment program? A single price for an episode of care is determined based on historical performance, factoring in all the services one wishes to include in a bundle (e.g. hospital, doctor visits in hospital, home physical therapy, follow-up doctor visits, follow up X-ray and labs for a defined time period). If the hospital, doctors, and others in the bundle generate new efficiencies in care (e.g. due to better care coordination, less wasteful test ordering, or lower implant/device costs), the savings are then distributed to these providers. What if spending exceeds the predetermined price? In some instances, the health plan bears the financial risk; in other instances, the hospital, physicians, and other bundle providers must pay back the shortfall. Important to note is that all sharing of savings is contingent on attainment of or improvement in demonstrated quality-of-care measures relevant to the bundle. In the future, bundling will evolve from shared savings to a single prospective payment for a care episode.

 

 

For now, most bundles encompass surgical procedures, although CMMI is working with health systems on several medical bundles, including acute MI, COPD, and stroke. All of these bundles are initiated by an acute hospitalization. Other types of bundles exist, such as with chronic conditions or with post-acute care only. In Massachusetts, a pediatric asthma bundle is being implemented through Medicaid, covering that population for a year or longer. The aim is to redirect dollars that normally would pay for ED visits and inpatient care to pay for interventions that promote better control of the disease and prevent acute flare-ups that lead to hospital visits.

How Hospitalists Fit In

To date, there has been little discussion of how physicians other than the surgeons doing the procedure (most bundles are for surgeries) fit into the clinical or financial model underpinning the program. However, with most patients in surgical or medical bundles being discharged to home, we now recognize that primary-care physicians (PCPs) will be essential to the success of a bundle.

Similarly, with medically complex patients enrolling in surgical bundles, hospitalists will be essential to the pre- and perioperative care of these patients. Also, transitioning bundle patients to home or to a rehabilitation will benefit from the involvement of a hospitalist.

What You Can Do Today

Although this might seem abstract for hospitalists practicing in the here and now, there are compelling opportunities for hospitalists who get involved in bundled-payment programs. Here’s what I suggest:

Find out if your hospital or post-acute facility is participating in bundling by looking at a map of CMMI bundle programs here: http://innovation.cms.gov/initiatives/bundled-payments;

  • Get a seat at the table working on the bundle; and
  • Negotiate a portion of the bundle’s shared savings on the basis of 1) increased efficiency and quality resulting from hospitalist involvement and 2) hospitalist direct oversight of bundled patients in post-acute facilities (if you choose).

Post-acute care may be new for your hospitalist program. Bundling programs are an important new business case for hospitalists in this setting.


Dr. Whitcomb is medical director of healthcare quality at Baystate Medical Center in Springfield, Mass. He is co-founder and past president of SHM. Email him at [email protected].

Issue
The Hospitalist - 2013(08)
Publications
Topics
Sections

With general agreement that health-care costs in the U.S. are unsustainable, the Centers for Medicare & Medicaid Services (CMS), through the Center for Medicare and Medicaid Innovation (CMMI), and the private sector are embarking on new approaches to cost containment. On the one hand, we have value-based purchasing (VBP), which rests on the existing fee-for-service system and aims for incremental change. On the other hand, we have accountable-care organizations (ACOs), which provide a global payment for a population of patients, and bundled-payment programs, which provide a single payment for an episode of care. These reimbursement models represent a fundamental change in how we pay for health care.

On a broad scale, ACOs may be further along in development than bundled-payment programs, even though pockets of bundling prototypes have existed for years. Examples include the Prometheus payment system, Geisinger’s ProvenCare, and CMS’ Acute Care Episode demonstration project, which bundled Part A (hospital) and Part B (doctors, others) payments for cardiac and orthopedic surgery procedures. Over the past two years, we have seen a dramatic uptick in bundling activity, including programs in a number of states (including Arkansas, California, and Massachusetts). Here at Baystate Health in Massachusetts, we kicked off a total-hip-replacement bundle with our subsidiary health plan in January 2011.

With most patients in surgical or medical bundles being discharged to home, we now recognize that PCPs will be essential to the success of a bundle.

Opportunities to contribute to bundled-payment programs

  • Work on teams to develop new care models for the program.
  • Optimize surgical patients preoperatively and comanage in the perioperative period to prevent complications.
  • Aid in ideal care transition from hospital to home or facility.
  • Provide direct post-acute-facility management to ensure ideal recovery and prevent readmissions.

Financial scenarios for hospitalists in bundled-payment programs

  • If hospitalists contribute to savings and are eligible to receive shared savings, such savings will represent a new revenue stream.
  • Hospitalists may be on the hook for care and costs over which they have little or no control (e.g. surgical or post-acute ambulatory care).
  • Hospitalists may be left out of bundled payments altogether and be paid solely fee for service.

Perhaps most notably, bundled payments are part of the Affordable Care Act. The Bundled Payments for Care Improvement initiative, launched earlier this year by CMMI, is enrolling traditional Medicare patients in bundled-payment programs across the country at more than 400 health systems.

How Bundled Payments Work

Bundled-payment programs provide a single payment to hospitals, doctors, post-acute providers, and other providers (for home care, lab, medical equipment, etc.) for a defined episode of care. Most bundles encompass at least an acute hospital episode and physician payments for the episode; many include some period after hospitalization, covering rehabilitation at a facility or at home and doctors’ visits during recovery. Bundling goes beyond Medicare’s diagnosis-related group (DRG) payments, which reimburse hospitals for all elements of an inpatient hospital stay for a given diagnosis but do not include services performed by nonhospital providers.

How do the finances work in a bundled-payment program? A single price for an episode of care is determined based on historical performance, factoring in all the services one wishes to include in a bundle (e.g. hospital, doctor visits in hospital, home physical therapy, follow-up doctor visits, follow up X-ray and labs for a defined time period). If the hospital, doctors, and others in the bundle generate new efficiencies in care (e.g. due to better care coordination, less wasteful test ordering, or lower implant/device costs), the savings are then distributed to these providers. What if spending exceeds the predetermined price? In some instances, the health plan bears the financial risk; in other instances, the hospital, physicians, and other bundle providers must pay back the shortfall. Important to note is that all sharing of savings is contingent on attainment of or improvement in demonstrated quality-of-care measures relevant to the bundle. In the future, bundling will evolve from shared savings to a single prospective payment for a care episode.

 

 

For now, most bundles encompass surgical procedures, although CMMI is working with health systems on several medical bundles, including acute MI, COPD, and stroke. All of these bundles are initiated by an acute hospitalization. Other types of bundles exist, such as with chronic conditions or with post-acute care only. In Massachusetts, a pediatric asthma bundle is being implemented through Medicaid, covering that population for a year or longer. The aim is to redirect dollars that normally would pay for ED visits and inpatient care to pay for interventions that promote better control of the disease and prevent acute flare-ups that lead to hospital visits.

How Hospitalists Fit In

To date, there has been little discussion of how physicians other than the surgeons doing the procedure (most bundles are for surgeries) fit into the clinical or financial model underpinning the program. However, with most patients in surgical or medical bundles being discharged to home, we now recognize that primary-care physicians (PCPs) will be essential to the success of a bundle.

Similarly, with medically complex patients enrolling in surgical bundles, hospitalists will be essential to the pre- and perioperative care of these patients. Also, transitioning bundle patients to home or to a rehabilitation will benefit from the involvement of a hospitalist.

What You Can Do Today

Although this might seem abstract for hospitalists practicing in the here and now, there are compelling opportunities for hospitalists who get involved in bundled-payment programs. Here’s what I suggest:

Find out if your hospital or post-acute facility is participating in bundling by looking at a map of CMMI bundle programs here: http://innovation.cms.gov/initiatives/bundled-payments;

  • Get a seat at the table working on the bundle; and
  • Negotiate a portion of the bundle’s shared savings on the basis of 1) increased efficiency and quality resulting from hospitalist involvement and 2) hospitalist direct oversight of bundled patients in post-acute facilities (if you choose).

Post-acute care may be new for your hospitalist program. Bundling programs are an important new business case for hospitalists in this setting.


Dr. Whitcomb is medical director of healthcare quality at Baystate Medical Center in Springfield, Mass. He is co-founder and past president of SHM. Email him at [email protected].

With general agreement that health-care costs in the U.S. are unsustainable, the Centers for Medicare & Medicaid Services (CMS), through the Center for Medicare and Medicaid Innovation (CMMI), and the private sector are embarking on new approaches to cost containment. On the one hand, we have value-based purchasing (VBP), which rests on the existing fee-for-service system and aims for incremental change. On the other hand, we have accountable-care organizations (ACOs), which provide a global payment for a population of patients, and bundled-payment programs, which provide a single payment for an episode of care. These reimbursement models represent a fundamental change in how we pay for health care.

On a broad scale, ACOs may be further along in development than bundled-payment programs, even though pockets of bundling prototypes have existed for years. Examples include the Prometheus payment system, Geisinger’s ProvenCare, and CMS’ Acute Care Episode demonstration project, which bundled Part A (hospital) and Part B (doctors, others) payments for cardiac and orthopedic surgery procedures. Over the past two years, we have seen a dramatic uptick in bundling activity, including programs in a number of states (including Arkansas, California, and Massachusetts). Here at Baystate Health in Massachusetts, we kicked off a total-hip-replacement bundle with our subsidiary health plan in January 2011.

With most patients in surgical or medical bundles being discharged to home, we now recognize that PCPs will be essential to the success of a bundle.

Opportunities to contribute to bundled-payment programs

  • Work on teams to develop new care models for the program.
  • Optimize surgical patients preoperatively and comanage in the perioperative period to prevent complications.
  • Aid in ideal care transition from hospital to home or facility.
  • Provide direct post-acute-facility management to ensure ideal recovery and prevent readmissions.

Financial scenarios for hospitalists in bundled-payment programs

  • If hospitalists contribute to savings and are eligible to receive shared savings, such savings will represent a new revenue stream.
  • Hospitalists may be on the hook for care and costs over which they have little or no control (e.g. surgical or post-acute ambulatory care).
  • Hospitalists may be left out of bundled payments altogether and be paid solely fee for service.

Perhaps most notably, bundled payments are part of the Affordable Care Act. The Bundled Payments for Care Improvement initiative, launched earlier this year by CMMI, is enrolling traditional Medicare patients in bundled-payment programs across the country at more than 400 health systems.

How Bundled Payments Work

Bundled-payment programs provide a single payment to hospitals, doctors, post-acute providers, and other providers (for home care, lab, medical equipment, etc.) for a defined episode of care. Most bundles encompass at least an acute hospital episode and physician payments for the episode; many include some period after hospitalization, covering rehabilitation at a facility or at home and doctors’ visits during recovery. Bundling goes beyond Medicare’s diagnosis-related group (DRG) payments, which reimburse hospitals for all elements of an inpatient hospital stay for a given diagnosis but do not include services performed by nonhospital providers.

How do the finances work in a bundled-payment program? A single price for an episode of care is determined based on historical performance, factoring in all the services one wishes to include in a bundle (e.g. hospital, doctor visits in hospital, home physical therapy, follow-up doctor visits, follow up X-ray and labs for a defined time period). If the hospital, doctors, and others in the bundle generate new efficiencies in care (e.g. due to better care coordination, less wasteful test ordering, or lower implant/device costs), the savings are then distributed to these providers. What if spending exceeds the predetermined price? In some instances, the health plan bears the financial risk; in other instances, the hospital, physicians, and other bundle providers must pay back the shortfall. Important to note is that all sharing of savings is contingent on attainment of or improvement in demonstrated quality-of-care measures relevant to the bundle. In the future, bundling will evolve from shared savings to a single prospective payment for a care episode.

 

 

For now, most bundles encompass surgical procedures, although CMMI is working with health systems on several medical bundles, including acute MI, COPD, and stroke. All of these bundles are initiated by an acute hospitalization. Other types of bundles exist, such as with chronic conditions or with post-acute care only. In Massachusetts, a pediatric asthma bundle is being implemented through Medicaid, covering that population for a year or longer. The aim is to redirect dollars that normally would pay for ED visits and inpatient care to pay for interventions that promote better control of the disease and prevent acute flare-ups that lead to hospital visits.

How Hospitalists Fit In

To date, there has been little discussion of how physicians other than the surgeons doing the procedure (most bundles are for surgeries) fit into the clinical or financial model underpinning the program. However, with most patients in surgical or medical bundles being discharged to home, we now recognize that primary-care physicians (PCPs) will be essential to the success of a bundle.

Similarly, with medically complex patients enrolling in surgical bundles, hospitalists will be essential to the pre- and perioperative care of these patients. Also, transitioning bundle patients to home or to a rehabilitation will benefit from the involvement of a hospitalist.

What You Can Do Today

Although this might seem abstract for hospitalists practicing in the here and now, there are compelling opportunities for hospitalists who get involved in bundled-payment programs. Here’s what I suggest:

Find out if your hospital or post-acute facility is participating in bundling by looking at a map of CMMI bundle programs here: http://innovation.cms.gov/initiatives/bundled-payments;

  • Get a seat at the table working on the bundle; and
  • Negotiate a portion of the bundle’s shared savings on the basis of 1) increased efficiency and quality resulting from hospitalist involvement and 2) hospitalist direct oversight of bundled patients in post-acute facilities (if you choose).

Post-acute care may be new for your hospitalist program. Bundling programs are an important new business case for hospitalists in this setting.


Dr. Whitcomb is medical director of healthcare quality at Baystate Medical Center in Springfield, Mass. He is co-founder and past president of SHM. Email him at [email protected].

Issue
The Hospitalist - 2013(08)
Issue
The Hospitalist - 2013(08)
Publications
Publications
Topics
Article Type
Display Headline
Bundled-Payment Program Basics
Display Headline
Bundled-Payment Program Basics
Sections
Disallow All Ads
Content Gating
No Gating (article Unlocked/Free)

Why Hospitalists Should Provide Patients with Discharge Summaries

Article Type
Changed
Wed, 03/27/2019 - 12:18
Display Headline
Why Hospitalists Should Provide Patients with Discharge Summaries

I continue to believe that hospitalists should routinely provide patients a copy of their discharge summary. I made the case for this in a 2006 column (“Keeping Patients in the Loop,” October 2006, p. 74), but I don’t see the idea catching on. I bet this simple act would have all kinds of benefits, including at least modest reductions in overall health-care expenditures and readmissions.

The whole dynamic of this issue seems to be changing as a result of “patient portals” allowing direct access to review test results and, in some cases, physician documentation. Typically, these are integrated with or at least connected to an electronic health record (EHR) and allow a patient, and those provided access (e.g. the password) by the patient, to review records. My own PCP provides access to a portal that I’ve found very useful, but I think, like most others, it doesn’t provide access to physician notes.

So there still is a case to be made for hospitalists (and all specialties) to provide copies of the discharge summary directly to patients and perhaps other forms of documentation as well.

Preparing a discharge summary the night before anticipated discharge can have many advantages, including improving discharge times the next morning. You can prepare the summary after routine rounding, when interruptions are less likely.

Timeliness

I think all discharge summaries should be completed before the patient leaves the hospital and amended as needed to capture any last-minute changes and details. The act of generating the summary often leads the discharging doctor to notice, and have a chance to address, important details that may have dropped off the daily problem list. Things like the need to recheck a lab test to ensure normalization prior to discharge, or make arrangements for outpatient colonoscopy to pursue the heme-positive stool found on admission, have sometimes slipped off the radar during the hospital stay and can be caught when preparing discharge summary.

Preparing a discharge summary the night before anticipated discharge can have many advantages, including improving early discharge times the next morning. And it means the doctor can prepare the summary late in the day after routine rounding is finished and interruptions are less likely. Although I think quality of care is enhanced by generating the summary the night before (and amending it as needed), I worked with a hospital that was cited by the Centers for Medicare & Medicaid Services (CMS) for doing this and was told they can’t be done prior to the calendar day of discharge.

Creation of the discharge summary isn’t the only relevant step. It should be transcribed on a stat basis (e.g. within two to four hours) and pushed to the PCP and other treating physicians. It isn’t enough that the document is available to the PCP via an EHR; these doctors need some sort of notice, such as an email.

To take advantage of the new “transitional-care management” codes (99495 and 99496), PCPs must make telephone contact with patients within two days of discharge and must have a face-to-face visit within one or two weeks of discharge (depending on whether the patient is high- or moderate-risk). Making the summary available to the PCP quickly can be crucial in ensuring these phone calls and visits are meaningful. (For an excellent review of the TCM codes, see Dr. Lauren Doctoroff’s article “New Codes Bridge Hospitals’ Post-Discharge Billing Gap” in the February 2013 issue of The Hospitalist.)

So I think both patients and other treating physicians should get the discharge summary on the day of discharge or no more than a day or two after. I bet this improves quality of care and readmissions, but one study found no association, and another found a trend toward reduced readmissions that did not reach statistical significance.1,2

 

 

Content

Just what information should go in a discharge summary? There are lots of opinions here, but it is worth starting with the components required by The Joint Commission. (You were aware of these, right?) The commission requires:

  • Reason for hospitalization;
  • Significant findings;
  • Procedures and treatment provided;
  • Patient’s discharge condition;
  • Patient and family instructions; and
  • Attending physician’s signature

To this list, I would add enumeration of tests pending at discharge.

The May/June 2005 issue of The Hospitalist has a terrific article by three thoughtful hospitalists titled “Advancing Toward the Ideal Hospital Discharge for the Elderly Patient.” It summarizes a 2005 workshop at the SHM annual meeting that produced a checklist of elements to consider including in every summary.

Brevity is a worthwhile goal but not at the expense of conveying the thought processes behind decisions. Things like how a decision was made to pursue watchful waiting versus aggressive workup now should be spelled out. Was it simply patient preference? It is common to start a trial of a medical therapy during a hospital stay, and it should be made clear that its effect should be assessed and a deliberate decision regarding continuing or stopping the therapy will be needed after discharge.

Lots of things need context and explanation for subsequent caregivers.

Format

The hospital in which I practice recently switched to a new EHR, and our hospitalist group has talked some about all of us using the same basic template for our notes. This should be valuable to all other caregivers who read a reasonable number of our notes and might improve our communication with one another around handoffs, etc. Although we haven’t reached a final decision about this, I’m an advocate for a shared template rather than each doctor using his or her own. This would be a worthwhile thing for all groups to consider.


Dr. Nelson has been a practicing hospitalist since 1988. He is co-founder and past president of SHM, and principal in Nelson Flores Hospital Medicine Consultants. He is co-director for SHM’s “Best Practices in Managing a Hospital Medicine Program” course. Write to him at [email protected].

References

  1. Hanson LO. Hospital discharge documentation and risk of rehospitalization. BMJ Qual Saf. 2011;20(9):773-778.
  2. Van Walraven C, Seth R, Austin PC, Laupacis A. Effect of discharge summary availability during post-discharge visits on hospital readmission. J Gen Intern Med. 2002;17(3):186-192.
Issue
The Hospitalist - 2013(08)
Publications
Topics
Sections

I continue to believe that hospitalists should routinely provide patients a copy of their discharge summary. I made the case for this in a 2006 column (“Keeping Patients in the Loop,” October 2006, p. 74), but I don’t see the idea catching on. I bet this simple act would have all kinds of benefits, including at least modest reductions in overall health-care expenditures and readmissions.

The whole dynamic of this issue seems to be changing as a result of “patient portals” allowing direct access to review test results and, in some cases, physician documentation. Typically, these are integrated with or at least connected to an electronic health record (EHR) and allow a patient, and those provided access (e.g. the password) by the patient, to review records. My own PCP provides access to a portal that I’ve found very useful, but I think, like most others, it doesn’t provide access to physician notes.

So there still is a case to be made for hospitalists (and all specialties) to provide copies of the discharge summary directly to patients and perhaps other forms of documentation as well.

Preparing a discharge summary the night before anticipated discharge can have many advantages, including improving discharge times the next morning. You can prepare the summary after routine rounding, when interruptions are less likely.

Timeliness

I think all discharge summaries should be completed before the patient leaves the hospital and amended as needed to capture any last-minute changes and details. The act of generating the summary often leads the discharging doctor to notice, and have a chance to address, important details that may have dropped off the daily problem list. Things like the need to recheck a lab test to ensure normalization prior to discharge, or make arrangements for outpatient colonoscopy to pursue the heme-positive stool found on admission, have sometimes slipped off the radar during the hospital stay and can be caught when preparing discharge summary.

Preparing a discharge summary the night before anticipated discharge can have many advantages, including improving early discharge times the next morning. And it means the doctor can prepare the summary late in the day after routine rounding is finished and interruptions are less likely. Although I think quality of care is enhanced by generating the summary the night before (and amending it as needed), I worked with a hospital that was cited by the Centers for Medicare & Medicaid Services (CMS) for doing this and was told they can’t be done prior to the calendar day of discharge.

Creation of the discharge summary isn’t the only relevant step. It should be transcribed on a stat basis (e.g. within two to four hours) and pushed to the PCP and other treating physicians. It isn’t enough that the document is available to the PCP via an EHR; these doctors need some sort of notice, such as an email.

To take advantage of the new “transitional-care management” codes (99495 and 99496), PCPs must make telephone contact with patients within two days of discharge and must have a face-to-face visit within one or two weeks of discharge (depending on whether the patient is high- or moderate-risk). Making the summary available to the PCP quickly can be crucial in ensuring these phone calls and visits are meaningful. (For an excellent review of the TCM codes, see Dr. Lauren Doctoroff’s article “New Codes Bridge Hospitals’ Post-Discharge Billing Gap” in the February 2013 issue of The Hospitalist.)

So I think both patients and other treating physicians should get the discharge summary on the day of discharge or no more than a day or two after. I bet this improves quality of care and readmissions, but one study found no association, and another found a trend toward reduced readmissions that did not reach statistical significance.1,2

 

 

Content

Just what information should go in a discharge summary? There are lots of opinions here, but it is worth starting with the components required by The Joint Commission. (You were aware of these, right?) The commission requires:

  • Reason for hospitalization;
  • Significant findings;
  • Procedures and treatment provided;
  • Patient’s discharge condition;
  • Patient and family instructions; and
  • Attending physician’s signature

To this list, I would add enumeration of tests pending at discharge.

The May/June 2005 issue of The Hospitalist has a terrific article by three thoughtful hospitalists titled “Advancing Toward the Ideal Hospital Discharge for the Elderly Patient.” It summarizes a 2005 workshop at the SHM annual meeting that produced a checklist of elements to consider including in every summary.

Brevity is a worthwhile goal but not at the expense of conveying the thought processes behind decisions. Things like how a decision was made to pursue watchful waiting versus aggressive workup now should be spelled out. Was it simply patient preference? It is common to start a trial of a medical therapy during a hospital stay, and it should be made clear that its effect should be assessed and a deliberate decision regarding continuing or stopping the therapy will be needed after discharge.

Lots of things need context and explanation for subsequent caregivers.

Format

The hospital in which I practice recently switched to a new EHR, and our hospitalist group has talked some about all of us using the same basic template for our notes. This should be valuable to all other caregivers who read a reasonable number of our notes and might improve our communication with one another around handoffs, etc. Although we haven’t reached a final decision about this, I’m an advocate for a shared template rather than each doctor using his or her own. This would be a worthwhile thing for all groups to consider.


Dr. Nelson has been a practicing hospitalist since 1988. He is co-founder and past president of SHM, and principal in Nelson Flores Hospital Medicine Consultants. He is co-director for SHM’s “Best Practices in Managing a Hospital Medicine Program” course. Write to him at [email protected].

References

  1. Hanson LO. Hospital discharge documentation and risk of rehospitalization. BMJ Qual Saf. 2011;20(9):773-778.
  2. Van Walraven C, Seth R, Austin PC, Laupacis A. Effect of discharge summary availability during post-discharge visits on hospital readmission. J Gen Intern Med. 2002;17(3):186-192.

I continue to believe that hospitalists should routinely provide patients a copy of their discharge summary. I made the case for this in a 2006 column (“Keeping Patients in the Loop,” October 2006, p. 74), but I don’t see the idea catching on. I bet this simple act would have all kinds of benefits, including at least modest reductions in overall health-care expenditures and readmissions.

The whole dynamic of this issue seems to be changing as a result of “patient portals” allowing direct access to review test results and, in some cases, physician documentation. Typically, these are integrated with or at least connected to an electronic health record (EHR) and allow a patient, and those provided access (e.g. the password) by the patient, to review records. My own PCP provides access to a portal that I’ve found very useful, but I think, like most others, it doesn’t provide access to physician notes.

So there still is a case to be made for hospitalists (and all specialties) to provide copies of the discharge summary directly to patients and perhaps other forms of documentation as well.

Preparing a discharge summary the night before anticipated discharge can have many advantages, including improving discharge times the next morning. You can prepare the summary after routine rounding, when interruptions are less likely.

Timeliness

I think all discharge summaries should be completed before the patient leaves the hospital and amended as needed to capture any last-minute changes and details. The act of generating the summary often leads the discharging doctor to notice, and have a chance to address, important details that may have dropped off the daily problem list. Things like the need to recheck a lab test to ensure normalization prior to discharge, or make arrangements for outpatient colonoscopy to pursue the heme-positive stool found on admission, have sometimes slipped off the radar during the hospital stay and can be caught when preparing discharge summary.

Preparing a discharge summary the night before anticipated discharge can have many advantages, including improving early discharge times the next morning. And it means the doctor can prepare the summary late in the day after routine rounding is finished and interruptions are less likely. Although I think quality of care is enhanced by generating the summary the night before (and amending it as needed), I worked with a hospital that was cited by the Centers for Medicare & Medicaid Services (CMS) for doing this and was told they can’t be done prior to the calendar day of discharge.

Creation of the discharge summary isn’t the only relevant step. It should be transcribed on a stat basis (e.g. within two to four hours) and pushed to the PCP and other treating physicians. It isn’t enough that the document is available to the PCP via an EHR; these doctors need some sort of notice, such as an email.

To take advantage of the new “transitional-care management” codes (99495 and 99496), PCPs must make telephone contact with patients within two days of discharge and must have a face-to-face visit within one or two weeks of discharge (depending on whether the patient is high- or moderate-risk). Making the summary available to the PCP quickly can be crucial in ensuring these phone calls and visits are meaningful. (For an excellent review of the TCM codes, see Dr. Lauren Doctoroff’s article “New Codes Bridge Hospitals’ Post-Discharge Billing Gap” in the February 2013 issue of The Hospitalist.)

So I think both patients and other treating physicians should get the discharge summary on the day of discharge or no more than a day or two after. I bet this improves quality of care and readmissions, but one study found no association, and another found a trend toward reduced readmissions that did not reach statistical significance.1,2

 

 

Content

Just what information should go in a discharge summary? There are lots of opinions here, but it is worth starting with the components required by The Joint Commission. (You were aware of these, right?) The commission requires:

  • Reason for hospitalization;
  • Significant findings;
  • Procedures and treatment provided;
  • Patient’s discharge condition;
  • Patient and family instructions; and
  • Attending physician’s signature

To this list, I would add enumeration of tests pending at discharge.

The May/June 2005 issue of The Hospitalist has a terrific article by three thoughtful hospitalists titled “Advancing Toward the Ideal Hospital Discharge for the Elderly Patient.” It summarizes a 2005 workshop at the SHM annual meeting that produced a checklist of elements to consider including in every summary.

Brevity is a worthwhile goal but not at the expense of conveying the thought processes behind decisions. Things like how a decision was made to pursue watchful waiting versus aggressive workup now should be spelled out. Was it simply patient preference? It is common to start a trial of a medical therapy during a hospital stay, and it should be made clear that its effect should be assessed and a deliberate decision regarding continuing or stopping the therapy will be needed after discharge.

Lots of things need context and explanation for subsequent caregivers.

Format

The hospital in which I practice recently switched to a new EHR, and our hospitalist group has talked some about all of us using the same basic template for our notes. This should be valuable to all other caregivers who read a reasonable number of our notes and might improve our communication with one another around handoffs, etc. Although we haven’t reached a final decision about this, I’m an advocate for a shared template rather than each doctor using his or her own. This would be a worthwhile thing for all groups to consider.


Dr. Nelson has been a practicing hospitalist since 1988. He is co-founder and past president of SHM, and principal in Nelson Flores Hospital Medicine Consultants. He is co-director for SHM’s “Best Practices in Managing a Hospital Medicine Program” course. Write to him at [email protected].

References

  1. Hanson LO. Hospital discharge documentation and risk of rehospitalization. BMJ Qual Saf. 2011;20(9):773-778.
  2. Van Walraven C, Seth R, Austin PC, Laupacis A. Effect of discharge summary availability during post-discharge visits on hospital readmission. J Gen Intern Med. 2002;17(3):186-192.
Issue
The Hospitalist - 2013(08)
Issue
The Hospitalist - 2013(08)
Publications
Publications
Topics
Article Type
Display Headline
Why Hospitalists Should Provide Patients with Discharge Summaries
Display Headline
Why Hospitalists Should Provide Patients with Discharge Summaries
Sections
Disallow All Ads
Content Gating
No Gating (article Unlocked/Free)